

# Intermedical Care and Lab Hospital Public Company Limited

# INVITATION TO THE 2025 ANNUAL GENERAL MEETING OF SHAREHOLDER MONDAY APRIL 28, 2025 AT 9.00 A.M.

At S.D. Avenue Hotel Pinklao Room 3rd Floor,

94 Borommarat Chachonnani Road, Bang Bamru, Bang Phlat, Bangkok 10700, Thailand

- FOR YOUR CONVENIENCE, THE PROXY HOLDER IS REQUIRED TO PRESENT THIS BARCODE REGISTRATION FROM TO THE REGISTRATION DESK.
- IN ORDER TO COMPLY WITH GUIDELINE FOR GOOD CORPORATE GOVERNANCE TO DECREASE OR CANCELLATION OF TOKEN GIVING AT THE AGM.





Intermedical Care and Lab Hospital Public Company Limited www.imhhospital.com



Ref. IMH 009/2025

#### March 28, 2025

- Subject : Invitation to attend the Annual General Meeting of Shareholders for the year 2025
  - : Shareholders of the Intermedical Care and Lab Hospital Public Company Limited
- Attachment

То

- 2. 2024 Annual Report (in from of QR code) ;
- 3. Profile of the Persons Nominated as Directors Replacing Those due to Retire upon Term Completion

1. Copy of the minutes of the 2024 Annual General Meeting of Shareholders on Thursday, April 18, 2024

- 4. Brief personal profiles and work experience of nominated auditors for the year 2025
- 5. Definition of "Independent Director"
- 6. Profile of Independent Directors being Nominated as Proxies by Shareholders
- 7. Company's Articles of Association Relating to the General Meeting of Shareholders
- 8. Document and Evidences Required for the Shareholder to Present for Meeting Attendance
- 9. Procedures for attending the 2025 Annual General Shareholders' Meeting
- 10. Proxy From A (General Proxy Form), Proxy From B (Specific Proxy Form (with detailed and fixed instructions) and Proxy From C (Proxy Form for Foreign Shareholders Appointing a Custodian in Thailand)11. Map of the Meeting Venue

Intermedical Care and Lab Hospital Public Company Limited has passed a resolution of the Board of Directors No. 1/2025 on Thursday, February 27, 2025 inviting the 2025 Annual General Meeting of Shareholders On <u>Monday, April</u> <u>28, 2025, at 09:00 AM.</u> at S.D. Avenue Hotel (Pinklao), Pinklao Room, 3rd Floor, No. 94 Borommaratchachonnani Road, Bamrung Subdistrict, Bang Phlat District, Bangkok 10700, to consider the following agenda:

#### Agenda 1 : To consider and adopt the minutes of the AGM of Shareholders for the Year 2024

<u>Purpose and Reason</u>: The Company sent the minutes of the 2024 Annual General Meeting of Shareholders on Thursday, April 18, 2024 The minutes were prepared within 14 days from the date of the Annual General Meeting of Shareholders. which was sent to the Stock Exchange of Thailand and the Ministry of Commerce within the time period specified by law. The minutes of the said meeting have also been published on the Company's website and the Company has sent a copy of the minutes along with the meeting invitation letter to the shareholders. According to the <u>attachment number 1</u>

**Board of Directors' opinion**: The Board of Directors has considered and is of the opinion that the minutes of the 2024 Annual General Meeting of Shareholders have been recorded completely and accurately in accordance with the resolutions of the shareholders' meeting and that it is appropriate to certify the minutes.

**Voting resolution** : Based on majority votes of the shareholders present at the meeting and having voting rights.

# Agenda 2 : To consider and acknowledge the operating results for the year 2024 and approve the annual financial statements ended on December 31, 2024

<u>Purpose and Reason</u>: Report on operating results for the year 2024 and financial statements for the year ending December 31, 2024 in accordance with financial reporting standards. which has been considered by the Audit Committee



and has been inspected and certified by an auditor. Details appear in the 2024 annual report in the section on consolidated financial statements. According to the <u>attachment number 2</u>

#### In summary, the main points are as follows:

Unit: million				
Details	2024	2023 (Newly updated)	2022	
Total assets	2,104.21	2,213.27	1,094.47	
Total debt	1,268.30	1,305.29	264.29	
Total shareholders' equity	835.90	907.98	830.18	
Value of paid-up shares	107.50	107.50	107.50	
Sales and service income	771.07	669.61	639.83	
Net profit (loss)	(77.88)	18.76	173.10	
Profit (loss) per share (baht / share)	(0.35)	0.009	0.81	

**Board of Directors' opinion**: It is considered that shareholders should approve the financial statements for the year ending 31 December 2024.

**Voting resolution** : Based on majority votes of the shareholders present at the meeting and having voting rights.

#### <u>Agenda 3</u> : <u>To consider and approve no profit allocation and no dividend payment for 2024.</u>

**Purpose and Reason** : The company has a policy of paying dividends to shareholders at a rate of not less than 40 percent of the company's net profits. Company financial statements after deducting taxes and legal reserves and other reserves (if any). However, The payment of such dividends will depend on cash flow, investment plans, and terms and conditions of various contracts that the Company is bound by including legal requirements other needs and appropriateness in the future as well In this regard, the resolution of The Board of Directors approved the suspension of profit allocation. and refrain from paying dividends for the year 2024 must be presented for approval from the shareholder meeting Except for the payment of interim dividends, which the Board of Directors has the authority to approve the payment of interim dividends. It will be reported to the shareholders' meeting at the next meeting.

Allocating reserve funds according to law must allocate 5 percent of net profits until reaching 10 percent of registered capital.Current registration of the company There is a total amount of legal reserve funds. 10,750,000.00 baht (Ten million seven hundred and fifty thousand baht only) which has reached 10 percent of the registered capital. Therefore, there is no need to allocate additional legal reserves.



**Board of Directors' opinion**: It is considered that shareholders should approve the omission of profit allocation. and refrain from paying dividends for 2023 Because the company It is necessary to maintain cash flow. for use in operations and supports the expansion of growth Future business, where the company has an investment plan that is appropriate and creates the greatest benefit to shareholders.

#### Information compared with dividend payout ratio

Separate financial statements	unit	2024 (Proposed Year)	2023	2022
1. Net profit (loss)	Million baht	36.82	(30.45)	5.12
2. Number of shares (excluding treasury shares)	Million baht	214.00	214.00	214.00
3. Dividends paid per share	Baht per share	0.00	0.00	0.14
4. Total dividends paid	Million baht	0.00	0.00	29.96
5. Dividend payout ratio to net profit	%	0.00	0.00	585.16*

\*Dividend payout ratio to net profit for 2022 is equal to 585.16% because the company Pay dividends from retained earnings

**Voting resolution** : Based on majority votes of the shareholders present at the meeting and having voting rights.

# Agenda 4 : To consider approve of the re-appointment of directors who retire by rotation and the nomination of a new director

<u>Purpose and Reason</u>: According to the Public Limited Companies Act B.E. 2535 and the Company's Articles of Association, Section 18, a regular general meeting of shareholders is required every time. One-third (1/3) of the total number of directors shall retire from office. and directors who have resigned from their positions may be re-elected. Currently, the company There are a total of 8 directors. In this general meeting of shareholders, there are 3 directors who are due to retire from their positions as follows:

Na	me	Position
1. Mr. Thanavath	Phonvichai	Independent Director / Chairman of the Board
2. Mr. Boonyarit	Kalayanamit	Independent Director / Chairman of the Audit Committee
3. Mr. Sukhum	Karnchannapimai	Director / Chairman of the Advisory Board

The Company has given shareholders the opportunity to nominate individuals they deem to have appropriate qualifications and do not have prohibited characteristics. To be considered for election as a director according to the criteria disclosed on the Company's website. From November 13, 2024 to February 14, 2025 however, it appears that no shareholder nominated any other person to be elected as a director.



The Nomination Committee (excluding directors with conflicts of interest) has reviewed the selection process in accordance with the company's established procedures. The committee has determined that the proposed candidates meet the relevant qualifications and regulatory requirements, as well as align with the company's business operations. Considering their qualifications, experience and expertise, the committee finds it appropriate to propose the reappointment of the three directors whose terms are expiring for another term.

**Board of Directors' opinion**: The Board of Directors (excluding directors with conflicts of interest) has individually assessed the qualifications of the nominated candidates for directorship. The nominees have undergone the company's prescribed selection process and meet all relevant regulatory requirements. They are well-suited for the company's business operations based on their professional skills, specialized expertise beneficial to the company, and past performance as board members and members of subcommittees. For the two independent director nominees, the Board has reviewed their qualifications and confirmed that they meet all legal and regulatory requirements for independent directors. Additionally, they possess expertise in management, finance, commerce, and the medical field, along with a diverse range of skills. Their ability to provide valuable advice to the company has helped navigate crises effectively. They are capable of offering independent opinions in full compliance with relevant regulations.

The three nominated directors meet all qualifications and do not have any prohibited characteristics as specified under Section 68 of the Public Limited Companies Act B.E. 2535 (including amendments) and the regulations of the Securities and Exchange Commission (SEC) and the Stock Exchange of Thailand (SET). Therefore, the Board of Directors approved the Nomination Committee's proposal to recommend the reappointment of the following individuals as directors for another term at the shareholders' meeting 1. Mr. Thanavath Phonvichai 2. Mr. Boonyarit Kalayanamit and 3. Mr. Sukhum Kanchanapimai

In this regard, the nominated person does not hold a position as a director/executive in any other business that may cause a conflict of interest or compete in business with the Company, and the Company has attached a biography of the person who has been nominated. Propose names for positions as directors, independent directors, and the definition of independent directors of the company. This is in accordance with the requirements of the Capital Market Supervisory Board. Details appear According to <u>attachment number 3</u>

<u>Voting resolution</u> : Based on majority votes of the shareholders present at the meeting and having voting rights. Voting in this agenda will be for individual directors.

#### Agenda 5 : To consider and approval of the directors' remuneration for the year 2025.

<u>Purpose and Reason</u>: In order to comply with the Company's regulations, Article 33., which stipulates that directors receive remuneration from the company. In the form of rewards, meeting allowances, gratuities, bonuses or other benefits in accordance with the regulations or as the shareholder meeting will consider. and the Nomination and Remuneration Committee The remuneration of directors and various sub-committee members for the year 2025 has been considered. which the Board of Directors Considered and agreed with the Nomination and Remuneration



Committee. and considered it appropriate to propose to the shareholder meeting to approve remuneration for the board of directors and sub-committees.

The directors' remuneration is determined in accordance with the criteria and policies established by the Board of Directors, following an initial review by the Nomination and Remuneration Committee. The remuneration is considered based on performance standards and the responsibilities of the directors. The company has set a clear and transparent remuneration policy, ensuring that the compensation remains at an appropriate and competitive level.

The criteria for determining the remuneration of directors will be based on the results of the evaluation of the performance of the Board of Directors, powers, duties and responsibilities. Growth and operating results of the company business liquidity and the performance of each director's duties including the amount of remuneration approved by the general meeting of shareholders. Amount of compensation paid in the past year and compare with the levels practiced in the same business group.

For the year 2025, the Nomination and Remuneration Committee has reviewed and proposed the directors' remuneration structure, which includes monthly compensation and meeting allowances, with a total amount not exceeding THB 3,500,000 (Three Million Five Hundred Thousand Baht). The details are as follows:

(Unit: Baht)

	Directors' Remuneration (Baht)				
Position	202		2024		
Position	(Propose	ed Year)			
	Monthly	Meeting	Monthly	Meeting	
	Compensation	Allowance	Compensation	Allowance	
		per Meeting		per Meeting	
Chairman of the Board	50,000	20,000	50,000	20,000	
Chairman of the Audit Committee	50,000	20,000	50,000	20,000	
Chairman of the Nomination and	-	20,000	-	20,000	
Remuneration Committee					
Non-Executive Director	20,000	12,000	20,000	12,000	
Executive Director	-	-	-	-	

Note: (1) Executive directors do not receive meeting allowances for the Board of Directors. and the Nomination and Remuneration Committee (2) Executive directors do not receive monthly compensation.

(3) Meeting allowance If there are more than 1 meeting within that month, you will receive meeting allowance only 1 time/month.



The consideration of the aforementioned remuneration criteria must be approved by the Board of Directors and shall not exceed the total amount approved by the Shareholders' Meeting.

<u>Board of Directors' opinion</u>: The Board of Directors, after consideration, recommends that the shareholders approve the directors' remuneration for the year 2025 in the form of monthly compensation and meeting allowances, with a total amount not exceeding THB 3,500,000 (Three Million Five Hundred Thousand Baht) the same as the previous year with no additional benefits.

<u>Voting resolution</u> : A two-third majority votes by the shareholders present at the meeting are required to pass the resolution.

### Agenda 6 : To consider and approve of the appointment of Auditor and determination of audit fee for the Year 2025.

Purpose and Reason : In order to comply with Article 58. of the Company's Articles of Association and the Public Limited Company Act 1992, which requires that the Annual General Meeting of Shareholders appoint the auditor and determine the remuneration every year. The Audit Committee has considered the performance of the auditors in the past year, experiences, readiness of personnel. the presence of accepted operating standards and have an opinion The auditors are knowledgeable, capable, and have good working standards. Have an understanding of the business of the Company Group and have independence in performing duties as well as being fully qualified according to the Company's regulations and regulations of the Securities and Exchange Commission Therefore, it was deemed appropriate to propose to the Board of Directors' meeting. To propose to the shareholders' meeting to consider the appointment of the Company's auditors for the year 2025 in the amount of 3 persons from Dharmniti Auditing Company Limited, whose names are as follows

1.	Miss. Soraya	Tintasuwan	Certified Public Accountant No. 8658
			Number of years of auditing in the past 7 years: 3 years
			(Sign your name on the company's financial statements for the year 2022-2024) or
2.	Miss. Sulalit	Ardsawang	Certified Public Accountant No. 7517 Number of years of auditing in the past 7 years: -None- or
			Number of years of additing in the past 7 years. None- of
3.	Mr. Peeradej	Phongsathiansa	k Certified Public Accountant No. 4752
			Number of years of auditing in the past 7 years: -None-

All 3 auditors are not shareholders of the company. No relationship with the company and does not provide consulting services to the Company in any way. Therefore, it is independent in auditing and expressing opinions on the



Company's financial statements. with detailed historical information and work experience of auditors According to attachment number 4

The company's auditor and subsidiaries Use the same auditing office which is independent no relationship or interest between the auditor and the company, subsidiaries, executives, major shareholders or those related to such persons in any way Therefore, they are independent in auditing and expressing opinions on the Company's financial statements.

Audit remuneration details proposed for 2025 as compared to 2024				
Company	2025	2024	change	(%)
Intermedical Care and Lab Hospital Public Company Limited				
1. Audit Fee	1,540,000	1,540,000	-	-
2. Non-Audit Fee	Actual cost	55,527	-	-

Board of Directors' opinion : The Board of Directors has considered the opinions of the Audit Committee. It is deemed appropriate to propose to the shareholder meeting to consider appointing (1) Ms. Soraya Tintasuwan, Certified Public Accountant No. 8658 or (2) Ms. Sullit Ardsawang, Certified Public Accountant No. 7517 or (3) Mr. Peeradej Phongsathiansak Certified Public Accountant No. 4752

On behalf of Dharmniti Auditing Company Limited, the Company's auditor for the year 2025 will be appointed by one person to inspect and express opinions on the Company's financial statements. And in the event that the certified public accountant mentioned above is unable to perform the job for the company Dharmniti Auditing Co., Ltd. hires other certified auditors of the company. Dharmniti Auditor Co., Ltd. on behalf of and should approve the audit fee of the company for the year 2025. The amount is 1,540,000 baht (one million five hundred and forty thousand baht) which does not include other service fees. related as proposed by the Audit Committee

**Voting resolution** : Based on majority votes of the shareholders present at the meeting and having voting rights.

#### <u>Agenda 7</u> : <u>To consideration of other matters (if any)</u>

The Board had no other matters to propose to the meeting for consideration. The Company provided an opportunity for shareholders to propose agenda items between November 13, 2024 and February 14, 2025 but it appeared that no shareholders proposed additional agenda items. meeting in advance

In this regard, the Board has set the date for determining the names of shareholders who have the right to attend the 2025 Annual General Meeting of Shareholders (Record Date) on March 21, 2025 (the XM sign will be posted or the day that they are not entitled to attend the meeting on March 20, 2025)



The company cordially invites all shareholders to attend the meeting on the specified date, time, and venue. Shareholders can scan the QR Code to access relevant meeting documents, which have also been published on the company's website www.imhhospital.com since March 28, 2025. This allows shareholders ample time to review the meeting agenda in advance. On the meeting day, registration will open at 07:00 AM using a Barcode System for a smooth and efficient check-in process. To expedite registration, shareholders and proxy holders attending the meeting are requested to bring the registration form, along with one of the following identification documents for verification National ID card or Passport or Government official ID card or Driver's license. These documents must be presented to the registration staff before entering the meeting, as detailed in the Shareholders' Meeting Attendance Rights document <u>attachment number 8</u>

For the convenience of shareholders, the company recommends granting a proxy to one of the Independent Directors, Ms. Tiwaporn Kantasuwan or Mr. Vorokas Tapasanan, to represent them at the meeting. Both Independent Directors have no special interests different from other directors in any agenda item. Details and profiles of the Independent Directors serving as proxy holders can be found in <u>attachment number 6</u> Shareholders are kindly requested to submit Proxy Form B <u>attachment number 10</u> to the company by April 18, 2025 at the following address:

> Company secretary Intermedical Care and Lab Hospital Public Company Limited 442 Bang Waek Road, Bang Waek Subdistrict, Phasi Charoen District, Bangkok 10160

If any shareholder has questions regarding the meeting or wishes to inquire about important company information, they may submit their questions in advance to the company via email at sirilux.r@intermedthai.com.

For questions submitted by shareholders or proxy holders prior to the meeting, the company will compile and address those related to the meeting agenda during the session. Other general inquiries or suggestions will be documented in the appendix of the Shareholders' Meeting Report, which will be published on the Stock Exchange of Thailand (SET) system and on the company's website (www.imhhospital.com) under the Investor Relations – Shareholders' Meeting section within 14 days after the meeting concludes.

Please be informed accordingly and requesting cooperation in action

Sincerely yours,

(Dr. Sittiwat Kamkatwong) Chief Executive Officer Intermedical Care and Lab Hospital Public Company Limited



#### Attachment 1

### Minutes of the Annual General Meeting of the Shareholders 2024 of Intermedical Care and Lab Hospital Public Company Limited

#### Date, time, and place

The meeting was held on Thursday, April 18, 2024, 09.00 hrs. At S.D. Avenue Hotel (Pinklao), Pinklao Room, 3th Floor, No. 94 Borommaratchachonnani Road, Bamrung Subdistrict, Bang Phlat District, Bangkok 10700

Total 21 shareholders attended the meeting in person, holding 108,444,328 shares, or 50.44 percent. There were 32 shareholders assigned a proxy holder, holding a total of 17,190,922 shares or 8.00 percent. Total 53 shareholders attending the meeting in person and via proxy holders held 125,635,250 shares or 58.44 percent of the paid-up 215,000,000 shares. Such number constituted a quorum as per articles of association Article 37. which stated that "In the meeting of shareholders, shareholders and proxies attending the meeting amounting to not less than 25 persons or not less than one half of the total number of shareholders, and in either case such shareholders shall hold shares amounting to an aggregate of not less than one-third (1/3) of all the shares sold of the Company". Accordingly, the chairman of the meeting commenced the Annual General Meeting of Shareholders for the year 2024.

Assoc. Prof. Dr. Thanavath Phonvichai, Chairman of the Board, chaired the meeting ("chairman of the meeting").

The chairman opened the meeting and assigned Miss Sirilux Rahong, the Company Secretary, introduced the Board of Directors of Intermedical Care and Lab Hospital Public Company Limited that attend the meeting amount 8 people by proportion of directors attending as the meeting equal to 100 percent as follows.

1. Assoc. Prof. Dr. Thanavath Phonvichai Independent Director / Chairman of the Board of Directors

		-
2. Mr. Boonyarit	Kalayanamit	Independent Director / Chairman of the Audit Committee
3. Dr. Sukhum	Karachanapimai	Director / Chairman of the Company's Advisor
4. Dr. Sittiwat	Kamkatwong	Director / Chairman of the Executive Committee / Chief Executive Officer
5. Miss Poramaporn	Pavarojkit	Director / Executive Committee / Deputy Chief Executive
		Officer / Chairman of the Corporate Social Responsibility Unit /
		Member of the Corporate Governance Unit / Member of the
		Nomination and Remuneration Committee / Member of the Risk
		Management Committee
6. Mr. Thibdee	Mangkalee	Director / Chairman of Risk Management Unit
7. Miss Tiwaporn	Kuntasuwon	Independent Director / Member of the Audit Committee /
		Member of the Corporate Governance Unit and Chairman of
		the Nomination and Remuneration Committee
8. Mr. Warokart	Tapsanant	Independent Director / Member of the Audit Committee /
		Chairman of the Corporate Governance Unit / Member of the
		Nomination and Remuneration Committee

Attending directors are as follows.

1. Miss Ratchanee	porn Mokkarawut	President of Accounting and Finance and Chief /
		Acting Accounting Manager / Member of Audit Committee
2. Miss Sirilux I	Rahong	Company Secretary
3. Miss Soraya	Tintasuwan	Auditor Dharmniti Auditing Company Limited

And thanks to Miss Sumana Rujichansiri, shareholder's rights protection volunteer from the Thai Investors Association who attended this meeting before conducting the meeting according to the agenda In order to make the vote counting transparent, the company assigned OJ International Co., Ltd. to be a witness for this vote counting.

Then, the meeting moderator informed all shareholders that the Company had invited and informed the information regarding the Annual General Meeting of Shareholders for 2024 to shareholders via 3 platforms.

- 1. Invitation to the meeting sent via QR Code Scanning to all shareholders by post.
- 2. Announcement in the newspaper.
- 3 Publication on the Company's website (www.imhhospital.com)

To ensure compliance with the good corporate governance regarding the voting in the meeting, the meeting moderator explained voting procedures and counting procedures.

1. In voting, majority votes are required. Every shareholder has one vote per share. In the event that a shareholder has a special interest in any matter Shareholders will not have the right to vote on that matter. In addition to voting for the election of directors according to Article 41 of the Company's Articles of Association. Agenda 6 The Company will propose to vote for each candidate nominated for directorship. For the resolution of Agenda 7 on consideration and approval of remuneration for the Company's directors for the year 2024, a vote of not less than two-thirds (2/3) of the shareholders attending the meeting and having the right to vote is required.

2. The shareholders will vote using the ballot provided for each agenda. The shareholders will mark for agreeing, disagree, or abstain on the ballot and sign his/her name on each ballot to identify the shareholder and ensure transparency. The ballots with disagree or abstain will be collected. After marking on the ballot, raise your hand for the staff to collect the ballot. Those who do not deliver the ballot are deemed as agreed with the resolution.

3 For counting votes, the disagree votes or abstain will be deducted from the total votes of shareholders attending the meeting, while the rest is counted as agreeing for each agenda.

For agree votes of each agenda, the ballots are returned to the company officer after the meeting is adjourned. Such voting procedures are transparent, and ballots are collected from all attendees to ensure transparency.

For questions or opinions other than the agenda pending consideration, please raise your questions or opinion in another agenda at the end of the meeting, and please ask a question or give an opinion in summary and please avoid repeating the same question or opinion to allow other shareholders to exercise their rights. We expect your cooperation to enable a smooth process and to maintain the duration within the time frame.

Mr. Thibdee Mangkalee, the director, to act as a meeting moderator ("meeting moderator")

**The meeting moderator** reported to the meeting that the Company had given the shareholders an opportunity to propose matters that they deemed appropriate to be included in the agenda of the shareholders' meeting and to nominate persons to be nominated as directors. The details, criteria and methods for proposing agenda items and nominating candidates have been published. to be considered for the election of company directors through the company's website. From November 14, 2023 to February 14, 2024, there was no shareholder proposing an agenda item or nominating a person to be nominated as a director.

When there were no questions raised concerning voting procedures, counting votes, and showing voting results, the meeting moderator proposed to the meeting to consider the agenda as follows.

## Agenda 1 To acknowledge the matters notified by the Chairman of the Board

**The chairman** Welcome to the shareholders and thank you to all shareholders who took their time to attend the 2024 Annual General Meeting of Shareholders of the Company and informed the meeting as follows:

1. The Company received the results of the assessment of the quality of the 2023 Annual General Meeting of Shareholders of companies listed on the Stock Exchange of Thailand with a score of 98 points (4 medals) from the Thai Investors Association.

2. The company has been assessed for corporate governance of listed companies CGR 2023 to be a company. that has corporate governance at level 5, the symbol or Excellent (Excellent CG Scoring) from the Thai Institute of Directors Association (IOD), supported by the Stock Exchange of Thailand

3. The Company operates its business by giving importance to anti-corruption. and adhere to morality, ethics, operate with transparency and be responsible to all stakeholders, such as requesting, accepting, offering or giving assets including any other benefits to government officials or any other person doing business with the Company. The Company has established guidelines for proper conduct of the Board of Directors, the Management and employees in business ethics and employee ethics which is part of The company is in the process of studying for membership in the anti-corruption sector of CAC. The said policy has been announced to the employees of the company thoroughly.

The chairman of the meeting allowed shareholders to inquire and express their opinions.

None of the shareholders inquired or expressed opinions.

**Resolution:** Since the first agenda is for informing purposes, there was no resolution required.

## Agenda 2 To consider and adopt the minutes of the 2023 Annual General Meeting of Shareholders.

**The meeting moderator** Proposed to the meeting to approve the minutes of the 2023 Annual General Meeting of Shareholders, held on April 29, 2023. The minutes of the shareholders' meeting have been sent to shareholders along with the meeting invitation letter.

**The meeting moderator** allowed the meeting to raise questions or suggestions for revising the content in the minutes of the meeting. When no shareholders raised any questions or suggested revising the meeting minutes, the meeting moderator asked for voting.

(While considering, there were 3 additional shareholders who joined the Meeting making the total to be 56 shareholders present and altogether 125,636,066 shares.)

**The meeting moderator** informed the meeting that this agenda must be affirmed by a majority of the votes of attending shareholders who voting.

Adopted the minutes of the 2023 Annual General Meeting of Shareholders, held on April 29, 2023 by the majority votes of the shareholders who attend the meeting and cast their votes as follows:

Approved by	125,636,066 vote	equivalent to	100.0000
Disapproved by	0 vote	equivalent to	0.0000
Abstained by	0 vote	equivalent to	0.0000
Voided ballot	0 vote	equivalent to	0.0000

**Resolution:** Adopted the minutes of the 2023 Annual General Meeting of Shareholders on Saturday, April 29, 2023

# <u>Agenda 3</u>: To acknowledge operating results of the Company for the year 2023 and approve the annual financial statements ended on December 31, 2023

The meeting moderator Propose the meeting to consider and acknowledge the operating results for the year 2023 and the annual financial statements ending December 31, 2023 in accordance with financial reporting standards. which has been considered by the Audit Committee and has been audited and certified by the auditor Details appear in the Annual Report 2023 under the topic of Financial Statements. which has already been sent in the form of QR CODE to the shareholders together with the invitation letter for this meeting.

### The key information was summarised as follows.

Statement of financial position of Intermedical Care and Lab Hospital Public Company Limited and subsidiary as of December 31, 2023.

Details	2023	2022	2021
Total assets	2,034.54	1,094.47	1,180.10
Total debt	1,204.43	264.29	335.70
Total shareholders' equity	830.10	830.18	844.40
Value of paid-up shares	107.50	107.50	107.50
Sales and service income	669.61	639.83	942.64
Net profit (loss)	21.75	173.10	422.70
Profit (loss) per share (baht / share)	0.10	0.81	1.97

Unit: Million Baht

In this agenda, the Thai Investors Association has determined that the Company Report on Anti-Corruption Policy corruption too which the company has given importance to the anti-corruption policy (Anti-Coorruption Policy) The said policy has been communicated to directors, executives and employees for acknowledgment through various channels of the company such as public relations boards, E-mail, Line Official and the Company's web site, and has a policy to receive complaints and clues. Whistle blowing to be able to report fraud in multiple channels

The meeting moderator allowed the meeting to raise questions. When no shareholders raised any questions or suggested this agenda, the meeting moderator asked the meeting to vote.

**The meeting moderator** informed the meeting that this agenda must be affirmed by a majority of the votes of attending shareholders who voting.

Approved the annual financial statements ended on December 31, 2023 by the majority votes of the shareholders who attended the meeting and cast their votes as follows:

Approved by	125,636,066 vote	equivalent to	100.0000
Disapproved by	0 vote	equivalent to	0.0000
Abstained by	0 vote	equivalent to	0.0000
Voided ballot	0 vote	equivalent to	0.0000

**Resolution:** Approved the annual financial statements ended on December 31, 2023

# <u>Agenda 4</u> To consider and approve the cessation of profit allocation. and refrain from paying dividends for 2023

The meeting moderator Inform the meeting that the Company has a policy to pay dividends to shareholders at a rate of not less than 40 percent of the net profit of the Company's financial statements after deducting taxes and legal reserves and other reserves (if any) However, the payment of such dividends will depend on cash flow, investment plans, terms and conditions of various contracts that the Company is bound by, as well as legal requirements. other necessity and suitability in the future as well, In this regard, the resolution of the Company's Board of Directors approved the suspension of profit allocation. and refrain from paying dividends for 2023 must be presented for approval from the shareholder meeting. Except for the payment of interim dividends, which the Board of Directors has the authority to approve the payment of interim dividends. It will be reported to the shareholder meeting at the next meeting.

Allocating reserve funds according to law must allocate 5 percent of net profits until reaching 10 percent of registered capital. Current registration of the company There is a total legal reserve fund of 10,750,000 baht (ten million seven hundred and fifty thousand baht only). which has reached 10 percent of the registered capital. Therefore, there is no need to allocate additional legal reserves.

#### Information compared with dividend payout ratio

Separate financial statements	unit	2023 (proposed year)	2022	2021
1. Net profit (loss)	Million baht	(30.45)	5.12	233.60
2. Number of shares (excluding treasury shares)	Million baht	214.00	214.00	214.00
3. Dividends paid per share	Baht per share	0.00	0.14	0.90
4. Total dividends paid	Million baht	0.00	29.96	192.60
5. Dividend payout ratio to net profit	%	0.00	585.16*	82.45

\*The dividend payout ratio for the year 2022 is 585.16% because the company Dividend payment from retained earnings

**The meeting moderator** allowed the meeting to raise questions. When no shareholders raised any questions or suggested this agenda, the meeting moderator asked the meeting to vote.

**The meeting moderator** informed the meeting that this agenda must be affirmed by a majority of the votes of attending shareholders who voting.

The meeting considered There was a resolution to approve the allocation of profits. and refrain from paying dividends for 2023 because the company It is necessary to maintain cash flow. for use in operations and support the expansion of business growth in the future, with the Company having an investment plan that is appropriate and creates the greatest benefit to shareholders. and do not have to allocate legal reserves This is because the legal reserve has reached 10 percent of the registered capital. The meeting has approved this agenda by simple majority as follows:

Approved by	125,636,066 vote	equivalent to	100.0000
Disapproved by	0 vote	equivalent to	0.0000
Abstained by	0 vote	equivalent to	0.0000
Voided ballot	0 vote	equivalent to	0.0000

**<u>Resolution</u>**: Approve to refrain from allocation of profits and refrain from paying dividends for 2023 because the company It is necessary to maintain cash flow. for use in operations and support the expansion of business growth in the future, with the Company having an investment plan that is appropriate and creates the greatest benefit to shareholders. and do not have to allocate legal reserves This is because the legal reserve has reached 10 percent of the registered capital.

# <u>Agenda 5</u> To consider and approve of the appointment of the Auditors and determination of the auditing fee for the Year 2023.

The meeting moderator Proposed to the meeting to consider and approve the appointment of auditors and determine their remuneration for the year 2024 and report to the meeting that In order to comply with the Company's Articles of Association, Article 58. and the Public Limited Company Act 1992 which requires that the Annual General Meeting of Shareholders appoint auditors and determine their remuneration every year. The Audit Committee has considered the performance of the auditors in the past year, experiences, readiness of personnel. the presence of accepted operating standards; and

have an opinion The auditors are knowledgeable, capable, and have good working standards. Have an understanding of the business of the Company Group and have independence in performing duties as well as being fully qualified according to the Company's regulations and regulations of the Securities and Exchange Commission Therefore, it was deemed appropriate to propose to the Board of Directors' meeting. To propose to the shareholders' meeting to consider the appointment of the Company's auditors for the year 2024 in the amount of 4 persons from Dharmniti Auditing Company Limited, whose names are as follows:

1. Miss. Soraya	Tintasuwan	Certified Public Accountant No. 8658 as the Company's auditor for the years 2022-2023, or 2 years. or
2. Miss. Sulalit	Ardsawang	Certified Public Accountant No. 7517 as the Company's auditor - None. Or
3. Miss. Methawee	Chanasongkram	Certified Public Accountant No. 12784 as the Company's auditor - None. or
4. Mr. Peradate	Pongsathiansak	Certified Public Accountant No. 4752 as the Company's auditor - None. or

All 4 auditors are not shareholders of the Company. No relationship with the company and does not serve as a consultant to the Company in any way, thus being independent in auditing and expressing opinions on the financial statements of the Company with detailed historical information and working experiences of auditors According to the <u>Attachment No. 3</u>

The company's auditor and subsidiaries Use the same auditing office which is independent no relationship or interest between the auditor and the company, subsidiaries, executives, major shareholders, or persons related to such persons in any way. The Company does not pay compensation for other services to the auditing firm that the auditor Affiliation Persons or businesses related to the auditor and the audit firm to which the auditor is affiliated.

Audit remuneration details proposed for 2024 as compared to 2023			Uni	t : Baht
Company	2024	2023	change	(%)
Intermedical Care and Lab Hospital Public Company Limited				
1. Audit Fee	1,540,000	1,540,000	-	-
2. Non-Audit Fee	Actual cost	100,586	-	-

The committee will ensure that the financial statements can be prepared in a timely manner on behalf of Dharmniti Auditing Co., Ltd. as the company's auditor for the year 2024, with one person to perform the audit and express opinions. The financial statements of the company and in the event that the above certified auditor is unable to perform the work, the company Dharmniti Auditing Co., Ltd. hires other certified auditors of the company. You can audit Dharmniti Accounting Limited instead and it is appropriate to approve the company's audit fee for the year 2024 in the amount of 1,540,000 baht (equal to last year) as proposed by the Audit Committee. which does not include other service fees related With the details presented above.

The meeting moderator gave the meeting an opportunity to ask questions and express their opinions on this agenda.

The meeting moderator allowed the meeting to raise questions. When no shareholders raised any questions or suggested this agenda, the meeting moderator asked the meeting to vote.

**The meeting moderator** informed the meeting that this agenda must be affirmed by a majority of the votes of attending shareholders who voting.

The meeting approved the appointment Miss Soraya Tintasuwan, Certified Public Accountant No. 8658 or Miss Sulit Atswang, Certified Public Accountant No. 7517 or Miss. Methawee Chanasongkram, Certified Public Accountant No. 12784 or Mr. Peeradej Pongsathien. divinity Certified Public Accountant No. 4752 in the name of Dharmniti Auditing Company Limited as the Company's auditor for the year 2024 by having one person to audit and express an opinion on the Company's financial statements and in the event that the aforementioned certified auditors are unable to perform their duties, the Company shall Dharmniti Audit Co., Ltd. Procure other certified auditors of the company. and it is appropriate to approve the auditing fee of the Company for the year 2024 in the amount of 1,540,000 baht (equal to last year) by the majority votes of the shareholders who attended the meeting and cast their votes as follows:

Approved by	125,636,066 vote	equivalent to	100.0000
Disapproved by	0 vote	equivalent to	0.0000
Abstained by	0 vote	equivalent to	0.0000
Voided ballot	0 vote	equivalent to	0.0000

**<u>Resolution</u>**: Approved the appointment of Ms. Soraya Tintasuwan, CPA No. 8658 or Ms. Sulalit Artsawang, CPA No. 7517 or Ms. Methawee Chanasongkram, CPA No. 12784 or Mr. Peeradet Pongsathiensak. CPA No. 4752 on behalf of Dharmniti Auditing Company Limited as the Company's auditor for the year 2024 and approved the audit fee of the company for the year 2024 in the amount of 1,540,000 baht.

# <u>Agenda 6:</u> To consider approve of the re-appointment of directors who retire by rotation and the nomination of a new director

**The meeting moderator** Proposed to the meeting to consider the election of directors to replace those who retired by rotation. and said that according to the Public Limited Companies Act B.E. 2535 and Article 18 of the Company's Articles of Association, every ordinary general One-third (1/3) of the total number of directors shall retire from office. and the outgoing directors may be re-elected. Currently the company There are a total of 8 directors. In this Annual General Meeting of Shareholders, there are 3 directors who are due to retire by rotation as follows:

Name		Position	
1. Dr. Sittiwat	Kamkatwong	Company Director (Authorized Signatory) / Executive Chairman/ Chief Executive Officer	
2. Miss Poramaporn Pavarojkit		Company Director (Authorized Signatory) / Nomination and Remuneration Committee / Executive Committee / Corporate Governance Working Group /	

Intermedical Care and Lab Hospital Public Company Limited

	Risk Management Working Group / Chairman of the Social Responsibility Working Group / Deputy Chief Executive Officer
3. Mr. Warokart Tapasanant	Independent Director / Audit Committee / Nomination and Remuneration Committee / Chairman of the Corporate Governance Working Group

Due to this agenda, all 3 directors will temporarily leave the meeting room. for the meeting to consider and express opinions independently and fully exercise their voting rights

The Company has given shareholders the opportunity to nominate individuals they deem to have appropriate qualifications and do not have prohibited characteristics. To be considered for election as a director according to the criteria disclosed on the Company's website. From 14 November 2023 to 14 February 2024 but it appears that no shareholder nominated any other person to be elected as a director. Nomination Committee This does not include directors who have conflicts of interest. Therefore, the suitability and qualifications according to the Public Company Limited Act B.E. 2535 have been considered. and announcements of the Stock Exchange of Thailand Office of the Securities and Exchange Commission and the Capital Market Supervisory Board determines

Nomination Committee Consideration has been made to select individual directors. According to the criteria and methods for recruiting individuals to be considered for election as company directors. We have considered the appropriateness that will benefit the Company's operations. Combined with the qualifications, knowledge, abilities, and experiences of directors who want to recruit to be diverse. and consistent with the company's business strategy by using an analysis of the skills, experience, knowledge, and expertise of the committee. Therefore, it is considered appropriate to propose Dr. Sittiwat Kamkatwong, Miss. Poramaporn Pavarojkit returned to serve as directors for another term. For Mr. Worokart Tapasanant, who is an independent director and has served as a director of the company for 4 years. The committee has considered and is of the view that the person nominated to be an independent director has the qualifications in accordance with the law regarding the requirements regarding independent directors. Therefore, it is considered appropriate to propose Mr. Worokart Tapasanant to return to the position of director for another term. In this regard, it is proposed to elect directors who must retire from office upon the said term. Individuals who are nominated to serve as directors have undergone a thorough screening and consideration process. with caution Both in terms of professional skills Specialized expertise that is beneficial to the company's business Including performance results as company directors and sub-committee members during the past period.

The meeting moderator allowed shareholders to raise a question and express their opinions.

The meeting moderator informed the meeting that this agenda must be affirmed by a majority of the votes of attending shareholders who voting.

The meeting approved the election of the 3 directors to replace the directors who retire by rotation to be directors of the Company for another term by voting for each director individually as per the following votes:

6.1 Dr. Sittiwat Kamkatwong (Director): The meeting resolved with the majority votes of the shareholders who attended the meeting and cast their votes as follows:

Approved by	125,636,066 vote	equivalent to	100.0000
Disapproved by	0 vote	equivalent to	0.0000

Intermedical Care and Lab Hospital Public Company Limited

Abstained by	0 vote	equivalent to	0.0000
Voided ballot	0 vote	equivalent to	0.0000

6.2 Miss Poramaporn Pavarojkit (Director): The meeting resolved with the majority votes of the shareholders who attended the meeting and cast their votes as follows:

Approved by	125,630,866 vote	equivalent to	99.9959
Disapproved by	5,200 vote	equivalent to	0.0041
Abstained by	0 vote	equivalent to	0.0000
Voided ballot	0 vote	equivalent to	0.0000

6.3 Mr. Worokart Tapasanant (Independent Director /Audit Committee): The meeting resolved with the majority votes of the shareholders who attended the meeting and cast their votes as follows:

Approved by	125,636,066 vote	equivalent to	100.0000
Disapproved by	0 vote	equivalent to	0.0000
Abstained by	0 vote	equivalent to	0.0000
Voided ballot	0 vote	equivalent to	0.0000

**The meeting moderator** Inviting all 3 directors to return to the meeting room. and congratulated everyone on returning continue to hold the position of director for another term.

As a result, there are 8 Directors on The Board of The Directors

1. Assoc. Prof. Dr. Thanavath P	honvichai
---------------------------------	-----------

- 2. Dr. Sukhum Karnchanapimai
- 3. Dr. Sittiwat Kamkatwong
- 4. Miss Poramaporn Pavarojkit
- 5. Mr. Thibdee Mangkalee
- 6. Mr. Boonyarit Kalayanamit
- 7. Miss Tiwaporn Kantasuwon
- 8. Mr. Worokart Tapasanant

**<u>Resolution:</u>** Approve to appoint 1. Dr. Sittiwat Kamkatwong 2. Miss Poramaporn Pavarojkit and 3. Mr. Worokart Tapasanant to repeat their positions for another term

### Agenda 7 To consider and approval of the directors' remuneration for the year 2024.

The meeting moderator Propose to the meeting to consider and approve the determination of compensation for company directors for the year 2024 and said to follow Article 33 of the Company's Articles of Association, which stipulates that directors will receive remuneration from the company in the form of prize money, meeting allowances, gratuities, bonuses, or other types of benefits. According to the regulations or the shareholder meeting will consider. and the Nomination and Remuneration Committee The remuneration of directors and various sub-committee members for the year 2024 has been considered. Considered and agreed with the Nomination and Remuneration for the board considered it appropriate to propose to the shareholder meeting to approve remuneration for the board

of directors and sub-committees starting from January 1, 2024 onwards until the shareholder meeting resolves to change otherwise.

Directors' remuneration is provided in accordance with the criteria and policies set by the Board of Directors. It has passed the first stage of consideration by the Nomination and Remuneration Committee. According to the work performance criteria and responsibilities of directors and the company has established a compensation policy. the Company's directors clearly and transparently The compensation is at an appropriate level.

For the year 2024, the Board of Directors Considered and proposed to determine the remuneration of various directors. in the form of monthly compensation and meeting allowances The total amount does not exceed 3,500,000 baht (three million five hundred thousand baht only) and has no other benefits. This is in accordance with the details of the proposal of the Nomination and Remuneration Committee which the Board of Directors has approved. The details are as follows:

		(Unit: Baht)	
	Directors' remuneration (Baht)		
Position	Monthly	Meeting allowance/time	
Chairman of the Board of Directors	50,000	20,000	
Chairman of the Audit Committee	50,000	20,000	
Chairman of the Nomination and Remuneration Committee	-	20,000	
Non-Executive Director	20,000	12,000	
Executive Director	-	-	

Note: (1) Executive directors do not receive meeting allowances for the Board of Directors. and the Nomination and Remuneration Committee (2) Executive directors do not receive monthly compensation.

(3) Meeting allowance If there are more than 1 meeting within that month, you will receive meeting allowance only 1 time/month.

**The meeting moderator** allowed the meeting to raise questions. When no shareholders raised any questions or suggested this agenda, the meeting moderator asked the meeting to vote.

**The meeting moderator** informed the meeting that the agenda must receive no less than twothirds (2/3) of total votes from the shareholders who attend the meeting and vote.

The meeting considered It was resolved to approve the determination of remuneration for company directors. and various sub-committees for the year 2024 in the form of monthly compensation and meeting allowances The total amount does not exceed 3,500,000 baht and has no other benefits. Starting from January 1, 2024 with the following votes:

Approved by	125,636,066 vote	equivalent to	100.0000
Disapproved by	0 vote	equivalent to	0.0000
Abstained by	0 vote	equivalent to	0.0000
Voided ballot	0 vote	equivalent to	0.0000

**Resolution:** Approved the determination of directors' remuneration and various sub-committees for the year 2024 in the form of monthly remuneration and meeting allowances for various committees. The total amount does not exceed 3,500,000 baht and has no other benefits. Starting from January 1, 2024 onwards as proposed.

### Agenda 8 Other business (if applicable)

-None-

(While considering, there were 4 additional shareholders who joined the Meeting making the total to be 60 shareholders present and altogether 125,660,291 shares.)

The meeting moderator allowed shareholders to express their opinions and suggestions on various matters.

**Dr. Sittiwat Kamkatwong (Chief Executive Officer)** speaking at the meeting Thank you to the shareholders who attended the 2024 Annual General Meeting of Shareholders. The shareholders did not have any questions or inquiries. Therefore, I would like to clarify the intent of this meeting on several agenda items as follows:

- 1. Remuneration of company directors for the year 2024, which is an agenda item with no questions. or any questions from shareholders. 4 years ago, in 2019, IMH was registered on the stock exchange. It can be seen that the directors have never received monthly compensation. until now
- 2. In 2021, IMH originally acquired the business of Prachapat Hospital The name was changed to IMH Thonburi Hospital with 100 beds and last year 2023 IMH acquired the business. Mahesak Hospital Currently, the name has been changed to IMH Silom Hospital with 132 beds. Therefore, the IMH hospital group now has a total of 232 beds, which has increased by more than 100% in the past 1 year. It is a hospital that has developed in leaps and bounds. resulting in last year's operating results being profitable Some came from Operation, some came from setting aside reserves for restructuring Mahesak Hospital. Therefore, we will refrain from paying dividends in 2023 for the maximum benefit of shareholders.
- 3. In the past year 2023, IMH has grown more than 100%. Currently, IMH is about to build a large IMH Bearing hospital with 300 beds, located on an area of 12 rai, next to BTS Bearing, near Bangna intersection, near Bangkok Mall. The largest modern shopping center in Thailand, 15 minutes from Suvarnabhumi Airport. IMH Bearing Hospital is now in the process of submitting an application for an environmental impact assessment report. (Environmental Impact Assessment; EIA), which is expected to be completed by the end of this year. As for the construction period, approximately 24 months, construction will be completed no later than 2027, with Architects 49 Company Limited or A49 being the designer. (One of the most respected architectural firms in Thailand) and in 2024 IMH has not yet taken over a new hospital.

4. At present, IMH has used loans from financial institutions. carefully and it is expected that there will be no impact on shareholders By issuing additional shares of the company's capital.

**Mr. Thitipong Sophonudomphon (shareholder)** asked what the budget for investment in IMH Bearing Hospital was.

The meeting moderator Said that the current interest rate has decreased on the loan of IMH Bearing Hospital, gradually building each building in sections. and will gradually open the service one building at a time.

**Dr. Sittiwat Kamkatwong (Chief Executive Officer)** Said that the main reason for IMH to build a new hospital is This is because when IMH goes to Take Over or buys the business, it will buy approximately 100 beds and it is a relatively old hospital.

Advantages of building a new hospital

- 1. Get a larger hospital with 300 beds.
- 2. The hospital design is quite modern.

**Mr. Somchai Thekingnam (shareholder)** asked about the operating results in 2021, 2022 and 2023, the profit percentage rate. Net in 2021 = 44%, 2022 = 26% and 2023 = 3.2%. When looking at the expense category in 2022, operating costs are 185 million baht and in 2023 = 312 million baht in the year. 2022 for administrative expenses of 103 million baht and 2023 = 161 million baht. Therefore, administrative expenses in 2022 = 430 million baht, increasing to 605 million baht. I would like to ask that while sales are similar. What is the cause of the increased costs?

**Miss. Ratchaneeporn Mokkarawut (Chief Financial Officer)** said that in 2021 and 2022, which was the epidemic period. COVID-19 in terms of Margin will be better and in the end of 2022 is the period to enter the hospital business. It is a period when there is rarely a COVID-19 epidemic, and in 2023 there will be investments, resulting in increased costs.

**Mr. Hangchai Akkhawasakul (on behalf of the shareholders Thai Investors Association)** offered suggestions and asked: Please help specify the name of the person who asked the question in the meeting report.

The meeting moderator Said that the company secretary should also specify the names of those asking questions at this meeting.

**Mr. Hangchai Akkhawasakul (on behalf of the shareholders Thai Investors Association)** He thanked the executives. If in the future there is fundraising to bring new shares to the Stock Exchange of Thailand. I would like to consider the portion of IPO shares that will offer new shares to existing shareholders who hold shares on the date that new shares are introduced into the IPO and become a listed company in the future. I would like to leave the president Should respect the rights of existing shareholders to have the right to purchase IPO shares. The meeting moderator Said that beside the said information there are already specified rules that must grant rights to shareholders.

**Mr. Hangchai Akkhawasakul (on behalf of the shareholders Thai Investors Association)** Inquire about Warrant shares or warrants for the purchase of common shares. How much is the conversion price? And what are the details of the holding period and expiration date? In order to give shareholders The future exercise of rights has been calculated.

**The meeting moderator** Said that IMH has not issued warrant shares because at the Extraordinary General Meeting of Shareholders No. 1/2023 on Monday, March 20, 2023, there was a resolution at the meeting not to approve the issuance of warrant shares.

**Mr. Thitipong Sophonudomphon (shareholder)** In the 2023 annual report (page 39), what are the details of 80% of the shares being held by IMH and the other 20%

Dr. Sittiwat Kamkatwong (Chief Executive Officer) Said 20% are partnerships of landowners. Location of IMH Bearing Hospital

**Mr. Hangchai Akkhawasakul (on behalf of the shareholders Thai Investors Association)** He praised the executives. and the team of officials who welcomed the shareholders at this meeting with great pride and was proud of 2 things as follows :

- 1. Ownership rights of investors and saw the importance of organizing an onsite meeting today to meet executives and shareholders but if possible, next year I would like to request that there be a Hybrid meeting, which is an Online and Onsite meeting at the same time. which can talk Communicate with each other as if you were in the same conference room. with modern technology platforms
- 2. Want to add to the story Increasing beds at IMH Bearing Hospital in preparation for increased personnel according to the size of the hospital. and in the future regarding medical care It may become another soft power field in medicine and public health.

**Ms. Sumana Rujichansiri (Thai Investors Association)** asked if looking at the information from the Department of Industrial Works. It is known that the factory has grown in size. I would like to ask what the executives' guidelines are for running the business.

**The meeting moderator** Said that the segment we are in and the segment of the Department of Industrial Works may be different segments.

The meeting moderator Inquired at the meeting whether any shareholders wished to ask for additional information. when no one asked further questions Then thanked and next in line to invite the chairman to close the meeting.

**Chairman of the meeting** Thank you to all shareholders and attendees who came to the meeting today. and gave suggestions to the company to the direction of growth The Board of Directors is committed to developing IMH to grow and stay relevant in the Thai medical industry. As for IMH Bearing Hospital, which

will be a large hospital. The Board of Directors has carefully considered various matters. and adhere to the interests of shareholders as important

Therefore, on the day of the 2024 Annual General Meeting of Shareholders this time, we would like to thank the shareholders very much for their kindness and asking questions and making suggestions on useful issues. And it is hoped that at the general shareholder meeting in 2025, there will be kindness from shareholders coming together to meet in unison. and presented good opinions For the benefit of further development of the company

At the closing time of the meeting, there were 26 shareholders attending the meeting in person, holding a total of 108,469,349 shares, representing 50.45 percent of the total shares. and 34 proxies holding a total of 17,190,942 shares, representing 8.00 percent of the total shares. In total, there were 60 shareholders both in person and by proxy, holding a total of 125,660,291 shares, representing 58.45 percent of the total paid-up shares of 215,000,000 shares.

The Meeting adjourned at 09.56 hrs

26 Signature .....

Chairman of the meeting

(Assoc. Prof. Dr. Thanavath Phonvichai)

Signature...

(Miss Sirilux Rahong)

. Company Secretary Person recording minutes of the meeting

## 2024 Annual Report (in form of QR code)





### Profile of the Persons Nominated as Directors Replacing

## Those due to Retire upon Term Completion

Name-Surname	- Associate Professor Dr. Thanavath Phonvichai
Type of directorship nomination	- Chairman of the Board
	- Independent Director
Date of Birth	- October 20, 1965
Age	- 59 years old
Nationality	- Thai
Education	- Doctor of Philosophy in Applied Statistics and Research Methods,
	University of Northern Colorado, USA
	- Master of Economics (Economic Development and Planning, with
	Honors), National Institute of Development Administration (NIDA),
	Thailand
	- Bachelor of Economics (Financial Economics, Second-Class Honors),
	Ramkhamhaeng University, Thailand
Date of Appointment	- February 3, 2020
Number of Years Served as a Director	- 5 years
Meeting Attendance in 2024	- Attended Board of Directors' meetings 4/4 or 100%
Training	
- Conducted by the Thai Institute of Directors	- Board Nomination and Compensation Program (Class 7/2019), IOD
Association (IOD)	- Advanced Audit Committee Program (Class 27/2017), IOD
	- Successful Formulation & Execution Strategy (Class 26/2016), IOD
	- Director Certification Program (Class 224/2016), IOD
	- Financial Statements for Directors (Class 31/2016), IOD
	- Director Accreditation Program (Class 51/2006), IOD
- Conducted by other institutions	- Executive Program in Trade and Commerce (TEPCoT), Class 2
Conducted by other institutions	- Executive Program (WTT), Class 16, Capital Market Academy
	- Executive Program in Energy Science (WP), Class 4, Energy Academy
	- National Defense Course (NDC), Class 57, National Defense College

<u>Work Experience (</u> Past 5 Years)	<ul> <li>Feb 2021 – Feb 2022: Independent Director, Government Housing Bank (GH Bank)</li> <li>2020 - 2021: President (Assistant Professor), University of the Thai</li> </ul>
	Chamber of Commerce
	• 2016 – 2019: Senior Vice President for Academic Affairs and Research,
	University of the Thai Chamber of Commerce
	• 2015 – 2019: Director, Rubber Authority of Thailand
Positions in Other Listed Companies	
(2 Organizations)	• 2020 – Present: Director, Muang Thai Insurance Public Company Limited
	(MTI)
	• 2015 - Present: Independent Director / Nomination and Remuneration
	Committee Member, Singha Estate Public Company Limited (S)
Positions in Other Organizations (Non-Listed Companies) (6 Organizations)	• July 2021 – Present: President (Associate Professor), University of the Thai Chamber of Commerce
	• 2014 - Present: Executive Director / Corporate Governance and CSR
	Committee, Government Lottery Office
	• 2014 - Present: Chairman of the Board, KPN Green Energy Solution Public
	Company Limited
	• Feb 2022 – Present: Independent Director, Government Savings Bank
	(GSB)
	• Feb 2022 – Present: Director, MFC Asset Management Public Company
	Limited
	• 2012 - Present: Independent Director / Chairman of the Audit Committee /
	Chairman of the Nomination and Remuneration Committee, Nakhonluang
	Capital Public Company Limited
Holding Directorships in Competing or Related	- None
Businesses	
Shareholding in the Company	- None
Shareholding Proportion in the Company	- None
Family Relationship with Executives	- None
Legal Disputes	- None
Expertise / Contributions as a Director	- Associate Professor Dr. Thanavath Phonvichai possesses extensive
	knowledge and expertise in management and finance. He has effectively applied
	his experience to fulfilling his duties as a board member, significantly contributing
	to the board's operations. He is also recognized for his strategic planning, problem-
	solving, and data analysis skills, all of which enhance the efficiency and excellence
	of the board's decision-making process.

Criteria for Director Nomination	- The Board of Directors has reviewed and concluded that
	Associate Professor Dr. Thanavath Phonvichai meets all legal qualifications for
	directorship. Given his extensive expertise and diverse professional background,
	the Board recommends his re-election at the Annual General Meeting of
	Shareholders. The nominee does not hold any directorships or executive positions
	in organizations that could lead to a conflict of interest with the company

#### Additional Qualifications for the Proposed Independent Director

Nature of Relationship	Qualification
1. Has any interest in the company, parent company, subsidiary, affiliate, or	
entities with potential conflicts of interest in the present or past 2 years	
1.1 Has served as an executive, employee, staff, or consultant with a	None
fixed salary	
1.2 Provides professional services (e.g., auditor, legal consultant)	None
1.3 Has significant business relations that may affect independence (e.g.,	None
sale/purchase of goods/services, loans)	
1.4 Is a close relative of executives or major shareholders	None
2. Has been appointed as a director representing a company, major	None
shareholders, or shareholders with related interests	

The nominee does not hold any directorships or executive positions in other entities that may cause a conflict of interest with the company



## Profile of the Persons Nominated as Directors Replacing

### Those due to Retire upon Term Completion

<ul><li>Independent Director</li><li>Chairman of the Audit Committee</li></ul>	
<ul> <li>October 7, 1961</li> <li>63 years old</li> <li>Thai</li> </ul>	
<ul> <li>Master's Degree in Economics, Western Michigan University, USA</li> <li>Bachelor of Science in Business Administration, Faculty of Economics and Business Administration, Kasetsart University, Thailand</li> </ul>	
- March 20, 2023	
- 2 years	
<ul> <li>Attended Board of Directors' meetings 4/4 or 100%</li> <li>Attended Audit Committee meetings 4/4 or 100%</li> </ul>	
- Director Accreditation Program (DAP), Class 205/2023, IOD	
<ul> <li>Senior Executive Program on China Business Knowledge and Cooperation (TEPCIAN), Class 2, University of the Thai Chamber of Commerce</li> <li>Executive Program in Trade and Commerce (TEPCoT), Class 6, University of the Thai Chamber of Commerce</li> <li>Senior Executive Program (NBS), Class 58</li> <li>The Practice of Trade Policy, Harvard Kennedy School, USA</li> <li>Strengthening Program for Ministerial Inspectors, Class of 2011</li> <li>High-Level Executive Training in National Defense (NDC),</li> </ul>	

	- Senior Executive Program, Capital Market Academy (CMA),
	Class 25
	- Advanced Insurance Science Program (AISP), Class 8
	- Advanced Agricultural Science Program (AASP), Class 2
	- Senior Executive Program in Energy Science (WP), Class 16,
	Energy Academy
Work Experience (Past 5 Years)	Government Sector Experience
	• 1986: Policy and Planning Analyst Level 3, Office of the National
	Economic and Social Development Council
	• 1986-1988: Economist Level 3-4, Department of Commercial
	Economics
	• 1988-1990: Trade Academic Level 4-5, Department of Foreign Trade
	• 1990-1995: Second Secretary – First Secretary (Commercial Affairs),
	Thai Trade Office, Permanent Mission in Geneva, Switzerland
	• 1995-1997: Commercial Affairs Advisor, Permanent Mission of
	Thailand to the World Trade Organization (WTO), Geneva, Switzerland
	• 1998-1999: Chief Assistant to the Minister's Secretariat, Ministry of
	Commerce
	• 1999-2003: Minister-Counsellor (Commercial Affairs), Thai Trade
	Promotion Office, Phnom Penh, Cambodia, Department of Export
	Promotion
	• 2003-2007: Director, Thai Trade Promotion Office, Istanbul, Republic
	of Turkey, Department of Export Promotion
	• 2007-2009: Director of the Bureau of Trade in Services and
	Investment Negotiations, Department of Trade Negotiations
	• 2009-2010: Deputy Director-General, Department of Trade
	Negotiations
	• 2010: Deputy Director-General, Department of Foreign Trade
	• 2010-2014: Inspector-General, Ministry of Commerce
	• 2014-2015: Director-General, Department of Internal Trade
	• 2015-2016: Ambassador and Permanent Representative of Thailand to
	the World Trade Organization (WTO), Geneva, Switzerland
	• 2016-2017: Director-General, Department of Trade Negotiations
	• 2017-2018: Director-General, Department of Internal Trade
	• 2018 - September 30, 2022: Permanent Secretary, Ministry of
	Commerce

<b>Board and Committee Experience</b>
• 2011-2012: Member, Selection Committee for Private Sector
Partnership in the Si Rat - Outer Ring Road Expressway Project
• 2011-2014: Director, Trade Siam Co., Ltd.
• 2012-2015: Director, Sugar Committee
• 2014: Director, Public Warehouse Organization
• 2014-2015: Director, Dairy Farming Promotion Organization of
Thailand
• 2014-2015: Director, National Rice Policy Committee
• 2014-2015: Director, National Cassava Policy Committee
• 2014-2015: Director, National Maize Policy Committee
• 2014-2015: Director, National Oil Palm and Palm Oil Policy
Committee
• 2014-2015: Member, Cement Fund for Central Storage Construction
(GPC)
• 2014-2022: Director, Anti-Dumping and Countervailing Committee
• 2017-2018: Director, Dairy Farming Promotion Organization of
Thailand
• 2017-2018: Member, National Advisory Council on Workforce
Development (Batch 16)
• 2017-2018: Director, Sugar Committee
• 2017-2018: Member, Cement Fund for Central Storage Construction
(GPC)
• 2017-2022: Director, National Rice Policy Committee
• 2017-2022: Director, National Cassava Policy Committee
• 2017-2022: Director, National Maize Policy Committee
• 2017-2022: Director, National Oil Palm and Palm Oil Policy
Committee
• 2018-2020: Director, Rubber Authority of Thailand
• 2018-2022: Executive Board, Senior Executive Program in Trade and
Commerce
• 2018-2022: Member, Public-Private Joint Committee on Science and
Technology (STC)
• 2018-2022: Director, Board of Investment (BOI)
• 2018-2022: Director, Tourism Authority of Thailand (TAT)
• 2018-2022: Director, Office of Insurance Commission (OIC)
• 2018-2022: Director, Securities and Exchange Commission (SEC)

Positions in Other Listed Companies	• 2022 – Present: Independent Director / Audit Committee Member,
(3 Organizations)	Thai Union Feedmill Public Company Limited (TFM)
	• 2022 – Present: Independent Director / Audit Committee Member,
	Posco - Thai Nox Public Company Limited (INOX)
	• 2022 – Present: Independent Director / Audit Committee Member, Prin
	Service Solution Public Company Limited (PRI)
Positions in Other Organizations (Non-Listed	• 2022 – Present: Independent Director, Big C Retail Corporation
Companies) (3 Organizations)	Public Company Limited
Companies) (5 Organizations)	• 2022 – Present: Expert Committee Member, Securities and Exchange
	Commission (SEC)
	• 2024 – Present: Expert Committee Member on Insurance, Office of Ins
	Commission (OIC)
Holding Directorships in Competing or Related	- None
Businesses	
Shareholding in the Company	- None
Shareholding Proportion in the Company	- None
Family Relationship with Executives	- None
Legal Disputes	- None
Expertise / Contributions as a Director	- Mr. Boonyarit Kalayanamit possesses extensive knowledge
	and expertise in management, commerce, strategic planning, and business
	problem-solving. He has demonstrated exceptional ability in market
	analysis and strategy development to effectively respond to changing
	trade environments. Throughout his tenure, he has applied his experience
	and knowledge to his role, contributing significantly to the company's
	board and operations. His leadership and strategic insights have been
	instrumental in driving the company's success, making him a valuable and
	influential executive in the organization.
Criteria for Director Nomination	- The Board of Directors has reviewed and concluded that
	Mr. Boonyarit Kalayanamit meets all legal qualifications required for a
	directorship. Furthermore, his diverse professional background and
	extensive expertise make him a highly qualified candidate. Therefore, the
	Board recommends his appointment for consideration and approval at the
	Annual General Meeting of Shareholders.
	, v

#### Additional Qualifications for the Proposed Independent Director

Nature of Relationship	Qualification
1. Has any interest in the company, parent company, subsidiary, affiliate, or	
entities with potential conflicts of interest in the present or past 2 years	
1.1 Has served as an executive, employee, staff, or consultant with a	None
fixed salary	
1.2 Provides professional services (e.g., auditor, legal consultant)	None
1.3 Has significant business relations that may affect independence (e.g.,	None
sale/purchase of goods/services, loans)	
1.4 Is a close relative of executives or major shareholders	None
2. Has been appointed as a director representing a company, major	None
shareholders, or shareholders with related interests	

The nominee does not hold any directorships or executive positions in other entities that may cause a conflict of interest with the company



## Profile of the Persons Nominated as Directors Replacing

## Those due to Retire upon Term Completion

Name-Surname	- Dr. Sukhum Kanchanapimai
Type of directorship nomination	- Director
	- Chairman of the Advisory Board
Date of Birth	- March 17, 1960
Age	- 64 years old
Nationality	- Thai
Education	- Doctor of Public Administration, Bangkok Thonburi University
	- Honorary Doctor of Philosophy in Medical Technology,
	Walailak University
	- Master of Public Administration (With Honors), National
	Institute of Development Administration (NIDA), Thailand
	- Doctor of Medicine (With Honors), Faculty of Medicine Siriraj
	Hospital, Mahidol University, Thailand
	- Bachelor of Laws, Sukhothai Thammathirat Open University,
	Thailand
	- Medical Board Certification in Internal Medicine, Medical
	Council of Thailand
	- Medical Board Certification in Cardiology, Medical Council of
	Thailand
	- Medical Board Certification in Family Medicine, Medical
	Council of Thailand
	- Medical Board Certification in Preventive Medicine (Public
	Health Specialty), Medical Council of Thailand
Date of Appointment	- March 20, 2023
Number of Years Served as a Director	- 2 years
Meeting Attendance in 2024	- Attended Board of Directors' meetings 4/4 or 100%

Training	
- Conducted by the Thai Institute of Directors	- Director Certification Program (DCP), Class 319/2022, IOD
Association (IOD)	
- Conducted by other institutions	- Advanced Insurance Science Program (AISP), Class 12, Office
	of Insurance Commission (OIC)
	- Thai-Chinese Leadership Program, Class 5, Huachiew
	Chalermprakiet University
	- Senior Executive Program in Energy Science, Class 15, Energy
	Academy
	- Senior Executive Program, Capital Market Academy (CMA),
	Class 28, Capital Market Academy
	- Advanced Management Science Program for Senior
	Executives, Class 2, Faculty of Public Administration, National
	Institute of Development Administration (NIDA)
	- Senior Executive Program in Urban Management (City
	Leadership Program, Class 3), Navamindradhiraj University
	- Executive Program in Trade and Commerce (TEPCoT), Class
	10, University of the Thai Chamber of Commerce
	- National Defense Course, Class 58, National Defense College,
	Institute of Defense Studies
	- Senior Inspector-General Program, Office of the Permanent
	Secretary, Office of the Prime Minister, in collaboration with
	the Office of the Civil Service Commission (OCSC)
	- Senior Executive Program in Justice Administration, Class 16,
	Institute of Justice Administration, Judicial Training Institute
	- Diplomatic Executive Program, Class 3, Devawongse
	Varopakarn Institute of Foreign Affairs, Ministry of Foreign
	Affairs
	- Senior Executive Program in Democracy and Governance,
	Class 14, College of Politics and Governance, King
	Prajadhipok's Institute
	- Senior Executive Program in Medical and Public Health
	Management, Class 23, Praboromarajchanok Institute, Ministry
	of Public Health
	Cardiology Specialty Training, Freeman Hospital, Newcastle
	University, United Kingdom
	• 2019 – 2022: President, The Medical Association of Thailand under
Work Experience (Past 5 Years)	the Royal Patronage
	<ul> <li>2018 – 2020: Permanent Secretary, Ministry of Public Health</li> </ul>

	• 2016 – 2018: Director-General, Department of Medical Sciences,
	Ministry of Public Health
	• 2013 – 2016: Inspector-General, Office of the Permanent Secretary,
	Ministry of Public Health
	• 2012 – 2013: Deputy Director-General, Department of Health Service
	Support, Ministry of Public Health
	• 2008 – 2012: Director, Chest Institute, Department of Medical Services,
	Ministry of Public Health
Positions in Other Listed Companies	• 2022 – Present: Independent Director / Audit Committee Member,
(1 Organizations)	Interlink Communication Public Company Limited (ILINK)
Positions in Other Organizations (Non-Listed	- None
Companies)	
Holding Directorships in Competing or Related	- None
Businesses	
Shareholding in the Company	- None
Shareholding Proportion in the Company	- None
Family Relationship with Executives	- None
Legal Disputes	- None
Expertise / Contributions as a Director	- Dr. Sukhum Kanchanapimai possesses extensive knowledge
	and expertise in both medicine and management. He has effectively
	applied his experience and insights to his role, contributing significantly
	to the company's board operations. In addition, he has strong skills in
	medical project planning and development, inter-agency coordination, and
	fostering collaboration with various organizations. His efforts have been
	instrumental in advancing healthcare policies and improving patient care
	systems, ensuring comprehensive and efficient medical services.
Criteria for Director Nomination	- The Board of Directors has reviewed and concluded that
	Dr. Sukhum Kanchanapimai meets all legal qualifications required for a
	directorship. His extensive expertise and diverse professional background
	make him a highly qualified candidate. Therefore, the Board recommends
	his appointment for consideration and approval at the Annual General
	Meeting of Shareholders.

The nominee does not hold any directorships or executive positions in other entities that may cause a conflict of interest with the company

# Brief personal profiles and work experience of nominated auditors

for the year 2025

Name	Miss Soraya Tintasuwan
	Auditor Registration No. 8658
	Dharmniti Auditing Co., Ltd.
Profiles and Work experience	
Working Period	Present - 2007
Professional Qualification	Certified Public Accountant (Thailand)
	Auditor Approved by the office of The Securities and
	Exchange Commission of Thailand
Academic Qualification	2008 : Master of Accounting (MACC) ,
	Chulalongkorn University
	2003 : Bachelor of Business Administration (BBA) in
	Accounting, Rajamankala University of Technology
	Thanyaburi
Experience	- Experience in external auditing more than 15 years
	has great expertise in the manufacturing business,
	Trading business, Healthcare business, Construction
	business, Transportation and logistics business,
	Provident funds and Mutual funds
Relationship with or Interest in (except for the audit	Has no relationship or interest with the Company,
service) the Company, Subsidiary, Executives, Major	executives, major shareholders or any person related to
Shareholders, or their Related Persons Capable of	such person in any way Therefore, they are independent
Undermining the Ability to Perform Duties	in auditing and expressing their opinions on the
Independently Contact Details	Company's financial statements.
Contact Details	Dharmniti Auditing Co., Ltd.
	178 Dharmniti Building, 6th - 7th Floor, Soi Permsap
	(Prachachuen 20), Prachachuen Road, Bang Sue,
	Bangkok 10800
	Telephone : (66) 0-2596-0500
	Facsimile : (66) 0-2596-0560

# Brief personal profiles and work experience of nominated auditors

# for the year 2025



Name	Miss Sulalit Ardsawang
	Auditor Registration No. 7517
	Dharmniti Auditing Co., Ltd
Profiles and Work experience	
Working Period	Present - 2002
Professional Qualification	Certified Public Accountant (Thailand)
	Auditor Approved by the office of The Securities and
	Exchange Commission of Thailand
Academic Qualification	2008 : Master of Business Administration (MBA) in
	Management, Srinakharinwirot University
	1993 : Bachelor of Business Administration (BBA) in
	Accounting, Ramkhamhaeng University
Experience	- Experience in external auditing more than 20 years
	- Experience in Due Diligence
	has great expertise in the manufacturing business, Trading
	business, Automotive leasing business, Healthcare business,
	Service and Printing business, Transportation and logistics
	business, Provident funds, Mutual funds and Property Funds
Relationship with or Interest in (except for the	Has no relationship or interest with the Company, executives,
audit service) the Company, Subsidiary,	major shareholders or any person related to such person in
Executives, Major Shareholders, or their Related	any way Therefore, they are independent in auditing and
Persons Capable of Undermining the Ability to	expressing their opinions on the Company's financial
Perform Duties Independently Contact Details	statements.
Contact Details	Dharmniti Auditing Co., Ltd.
	178 Dharmniti Building, 6th - 7th Floor, Soi Permsap
	(Prachachuen 20), Prachachuen Road, Bang Sue, Bangkok
	10800
	Telephone : (66) 0-2596-0500
	Facsimile : (66) 0-2596-0560

# Brief personal profiles and work experience of nominated auditors

# for the year 2025



Name	Mr. Peradate Pongsathiansak
	Auditor Registration No. 4752
	Dharmniti Auditing Co., Ltd
Profiles and Work experience	
Working Period	Present - 2002
Professional Qualification	Certified Public Accountant (Thailand)
	Auditor Approved by the office of The Securities and
	Exchange Commission of Thailand
Academic Qualification	2005: Mini MBA, Thammasrt University
	1990 : Bachelor of Business Administration in Accounting,
	Ramkhamhaeng University
Experience	- Experience in external auditing more than 20 years
	- Experience in Due Diligence more than 20 years
	- Experience in accounting system 13 <sup>th</sup> Asian Games and
	7 <sup>th</sup> FESPIC Games
	has great expertise in the manufacturing business, Trading
	business, Real estate business, Construction business,
	Hotel business, Healthcare business, Provident funds and
	Mutual funds
Relationship with or Interest in (except for the audit	Has no relationship or interest with the Company,
service) the Company, Subsidiary, Executives,	executives, major shareholders or any person related to
Major Shareholders, or their Related Persons	such person in any way Therefore, they are independent in
Capable of Undermining the Ability to Perform	auditing and expressing their opinions on the Company's
Duties Independently Contact Details	financial statements.
Contact Details	Dharmniti Auditing Co., Ltd.
	178 Dharmniti Building, 6 <sup>th</sup> - 7 <sup>th</sup> Floor, Soi Permsap
	(Prachachuen 20), Prachachuen Road, Bang Sue,
	Bangkok 10800
	Telephone : (66) 0-2596-0500
	Facsimile : (66) 0-2596-0560

# **Definitions of "Independent Director"**

#### The company has given the following definitions of an "independent director" based on the notification

#### of

#### The Capital Market Supervisory Board

1. Holding shares not exceeding 1 percent of the total number of voting rights of the company, its parent company, subsidiary, affiliate, major shareholders or controlling person of the company, including the shares being held by related persons of independent directors.

2. Neither being nor having been an executive director, employee, staff, or advisor who received regular salaries, or being a controlling person of the company, its parent company, subsidiary, affiliate, same-level subsidiary, major shareholders or persons having supervision authority over the company, unless the foregoing status ended not less than two years prior to the date of their appointments as independent directors.

3. Not being a person related by blood or registration under laws, such as father, mother, spouse, sibling, and child, including spouse of the children, executive, major shareholder, controlling person, or person to be nominated as executive or as controlling person of the company or its subsidiary.

4. Not having business relationship with the company, its parent company, subsidiary, affiliate, major shareholders or controlling person of the company, in such manner likely to interfere with own independent judgement, and neither being nor having been a significant shareholder or person having supervision authority over the person who has business relationship with the company, its parent company, subsidiary, affiliate, major shareholders or controlling person of the company, unless the foregoing relationship ended not less than two years prior to the date of appointment as independent director.

5. Neither being nor having been an auditor of the company, its parent company, subsidiary, affiliate, major shareholders or controlling person of the company, and not being a significant shareholder or person having supervision authority, or partner of an audit firm which employs auditors of the company, its parent company, subsidiary, affiliate, major shareholders or controlling person of the company, unless the foregoing relationship has ended not less than two years prior to the date of appointment as independent director.

6. Neither being nor having been any professional advisor including legal advisor or financial advisor who receives an annual service fee exceeding two million Baht from the company, its parent company, subsidiary, affiliate, major shareholders or controlling person of the company, and not being a significant shareholder or person having supervision authority or partner of the professional advisor, unless the foregoing relationship has ended not less than two years prior to the date of appointment as independent director.

7. Not being a director who has been appointed as the representative of the company's director, major shareholder, or being a shareholder who is related to the major shareholder.

8. Not engaging in business operations of the same business nature or in competition against the business operations of the company or its subsidiaries, nor serving as a significant partner in a limited partnership or otherwise serving as a director participating in the management, or serving as employee or consultant receiving regular salary or holding over 1 percent shares out off total shares in other companies engaging in the same business nature or in competition against the company and its subsidiaries.

9. Not having any characteristics which make him incapable of expressing independent opinions with regard to the company's business affairs.

# Profile of Independent Directorsbeing Nominated as Proxiesby Shareholders



# 2. Miss Tiwaporn Kuntasuwon

Independent Director / Audit Committee / Chairman of the Nomination and Remuneration Committee / Corporate Governance Working Group Age : 55 years old Address : Intermedical Care and Lab Hospital Public Company Limited 442 Bangwaek road, Bangwaek sub-district, Phasi Charoen district, Bangkok, 10160, Thailand Company shareholding : 50,000 shares or 0.02 percent of the total shares with voting Rights Special interest : None



#### 3. Mr. Warokart Tapasanant

Independent Director / Audit Committee / Chairman of the Corporate Governance Working
Group / Nomination and Remuneration Committee
Age : 48 years old
Address: Intermedical Care and Lab Hospital Public Company Limited
442 Bangwaek road, Bangwaek sub-district, Phasi Charoen district, Bangkok, 10160, Thailand
Company shareholding: 40,000 shares or 0.02 percent of the total shares with
voting rights

Special interest : None

# Articles of Association relating to the shareholders' meeting and voting

#### 1. Closing of register book

#### Section 2 Article 4.

During the twenty (21) days prior to the shareholders' meeting, the company may close the register book and cease the transfer registration by giving notice to shareholders at the head office and all branch office at least fourteen (14) days prior to the ceasing of registration. In case the of listed securities in the Stock Exchange of Thailand, the closing and ceasing of registration shall be in accordance to the securities and stock exchange law.

#### 2. Call for a meeting

#### Section 4 Article 34.

The shareholders' meeting shall be held in the place where the head office is located or the provinces nearby.

#### Section 4 Article 35.

The Board of Directors may call a shareholders' meeting at least once a year which shall be called "Ordinary Meeting" and shall be convened within four (4) months from the last day of the fiscal year of the Company.

The other meetings of shareholders shall be called "Extraordinary General Meeting". As it is deemed necessary or appropriate, the Board of Directors may summon an Extraordinary General Meeting of Shareholders. Or, shareholders holding shares in aggregate of not less than one-tenth (1/10) of the total number of shares sold, may at any time submit their names and request the Board of Directors in writing to call for an Extraordinary General Meeting of Shareholders, provided that, the reasons for the request to call such meeting shall be clearly stated in the said written request. In such an event, the Board of Directors shall proceed to call a shareholders' meeting to be held within forty five (45) days from the date of the receipt of such request from the said shareholders.

In the event the Board of Directors does not convene the meeting within forty five (45) days from the date receipt letter of a shareholder, shareholders holding shares in aggregate to constitute a quorum may call for a meeting within forty five (45) days from the due date as prescribed above, and it shall be deemed as a shareholders' meeting called by the Board of Directors. The company shall then responsible for the expense rising out of the meeting and facilities as appropriate. If the number of shareholders does not constitute a quorum, those shareholders who request for such meeting shall compensate the expense rising thereof to the company.

#### Section 4 Article 36.

In calling a shareholders' meeting, the Board of Directors shall prepare a written notice specifying the place, date, time, agenda of the meeting and the matters to be proposed to the meeting in appropriate detail by clearly indicating whether it is a matter proposed for acknowledgment or for approval or for consideration, as the case may be, including the opinion of the board of directors on the said matters. The said notice shall be distributed to the shareholders and the MOC's registrar not less than seven (7) days prior to the date of the meeting. The notice shall be published in the newspaper for not less than three (3) consecutive days and not less than three (3) days prior to the date of the meeting.

### 3 Proxy

### Section 4, Article 38

The shareholders may appoint another person as their proxy to attend the meeting and vote on their behalf

The proxy shall be made in written form signed by the shareholder as stated by the MOC's registrar, and delivered to to chairman of the board or any person as assigned by the chairman, at the place of the meeting prior to the proxy holder will attend to the meeting. Additionally, details shall consist of at least following list:

- (1) Shares hold by the shareholder
- (2) Name of proxy holder
- (3) Number of the meeting where the proxy holder is authorized to attend and vote

#### 4. Conduct of a meeting

#### Section 4 Article 39.

The meeting shall proceed according to the agendas respectively as specified in the notice unless the shareholders' meeting resolved to change the agenda by the affirmative votes of the shareholders holding not less than two-third (2/3) of the shareholders attended the meeting.

All agendas specified under the first paragraph have been considered, shareholders holding not less than one-third (1/3) of the total number of distributed shares may request the meeting to consider other matters not specified in such notice.

If the meeting is unable to conclude consideration of the matters according to the sequence of the agenda as provided in invitation letter to the meeting and it is necessary to postpone the consideration of the meeting, the meeting shall determine the place, date and time for the next meeting and the Board of Directors shall, not less than seven (7) days prior to the date of the meeting, deliver to the shareholders notice calling the meeting which indicates the place, date, time and the agenda of the meeting. The notice calling the meeting shall also be published in a newspaper for three (3) consecutive days not less than three (3) days prior to the date of the meeting.

#### Section 4 Article 40.

The chairman of the board of directors shall act as chairman of the shareholders' meeting. In the case that he is absent or is unable to perform the duty and if there is the vice-chairman, the vice-chairman shall act as chairman. In the absence of both the chairman of the board of directors and vice-chairman or they are unable to perform the duty, the meeting shall elect one of the shareholders present to act as chairman of the meeting.

### 5. Quorum

#### Section 4 Article 37.

At the meeting of shareholders, in order to constitute a quorum, there shall be shareholders and proxies (if any) attending the meeting amounting to not less than twenty-five (25) persons or not less than one half of the total number of shareholders, and in either case such shareholders shall hold shares amounting to an aggregate of not less than one-third of all the shares sold of the Company. At any meeting of shareholders, if one (1) hour has passed since the time specified for the meeting and the number of shareholders attending the meeting is not enough to constitute a quorum as prescribed; if such meeting of shareholders was called as a result of a request by the shareholders, such meeting shall be cancelled; if such meeting was not called as a result of a request by the shareholders, the meeting shall be called once again and the notice calling such meeting shall be delivered to shareholders not less than seven (7) days prior to the date of the meeting. In this subsequent meeting, a quorum as stated in Article 37 is not required.

# 6. Casting votes

#### Section 4 Article 41.

Each shareholder shall have a number of votes equal to the number of shares held where one share represents one vote. Any shareholder who has a special interest in any matters shall not be entitled to vote, except for voting on the election of directors.

#### Section 4 Article 42.

Unless this Articles of Association or the laws provide otherwise, a resolution of the shareholders' meeting or approval on any matters shall require a majority of votes of the shareholders who are present at the meeting and vote. In the case of a tie, the presiding Chairman shall have another casting vote.

For the following cases, a vote of not less than three-fourths (3/4) of the total number of votes of the shareholders attending the meeting and having the right to vote is required:

- the sale or transfer of the whole or the substantial part of the Company's business to any other person;
- (2) the purchase or acceptance of transfer of the business of private companies or public companies by the Company
- (3) the making, amending or terminating of any agreement with respect to the granting of a lease of the whole or substantial parts of the Company's business, the assignment of the management of the business of the Company to any person, or the amalgamation of the business with other persons for the purpose of profit and loss sharing;
- the amendment of the Memorandum of Associations or Articles of Association of the Company;
- (5) the increasing or reducing the Company's capital;
- (6) the issuance of debenture stock
- (7) the amalgamation or dissolution of the company

### 7. Appointment of directors

Section 3 Article 17.

The meeting of shareholders elect directors under following criteria and methods:

- (1) The right to vote is equal to the number of share hold
- (2) Each shareholder may exercise all the votes he or she has to elect one or several persons as director or directors, but the shareholder cannot be divided his or her votes to any person in any number
- (3) Persons who receive the highest votes arranged in order from higher to lower in a number equal to that of the number of directors to be appointed are elected to be the directors of the Company. In the event of a tie at a lower place, which would make the number of directors greater than that required, the chairman of the meeting will have a casting vote.

### **Documents and Evidences Required for the Shareholder**

### to Present for Meeting Attendance

The Company will use a barcode system for the registration, therefore <u>please brings documents delivered by the Company to each</u> of the shareholders together with the notice for calling the meeting, on which the relevant barcode is printed for meeting registration purpose.

The attendants must present the following documents for registration before attending the meeting (as the case may be):-

#### 1. In the event that the shareholder is an ordinary person:

1.1 In case of attendance in person:

- A valid official ID card where a photograph of shareholder is shown, e.g. personal ID card, driving license, or passport (in case of a foreigner)

1.2 In case of attendance by proxy:

- A Proxy Form as provided in attachment 12, completely filled, signed by proxy grantor and the proxy, together with Baht 20 of stamp duty affixed.

- A copy of the proxy grantor\*s and proxy holders\* official ID cards as referred to in 1.1 above certified as true and correct by them

- An original copy of the proxy grantor\*s official ID card as referred to in 1.1 above

#### 2. In the event that the shareholder is a juristic person:

2.1 In case of attendance in person by the authorized person:

- An original copy of the authorized representative\*s official ID card as referred to in 1.1 above with one copy certified as true and correct.

- A copy of Affidavit or Certificate of Incorporation of the shareholder showing that the name of the person who signs in the Proxy Form as the grantor is an authorized representative of the shareholder having authority to act on the shareholders\* behalf and such copy of the Affidavit or Certificate of Incorporation must be certified as true and correct by such authorized representative.

2.2 In case of attendance by proxy:

- A Proxy Form provided as in attachment 12, completely filled, and signed by the proxy grantor and the proxy, together with Baht 20 of stamp duty affixed.

- A copy of Affidavit or Certificate of Incorporation of the shareholder showing that the name of the person who signs in the Proxy Form as the grantor is an authorized representative of the shareholder having authority to act on the shareholders\* behalf and such copy of the Affidavit or Certificate of Incorporation must be certified as true and correct by such authorized representative.

- copies of the authorized representative\*s and proxy\*s official ID cards as referred to in 1.1 above with a certification of true and correct copy.

#### 3. In the event that the shareholder is a non-Thai shareholder or is a juristic person incorporated under a foreign laws:

Paragraph no. 1 and 2 above shall be applied mutatis to a non-Thai shareholder or attendant of meeting or, as the case may be, a shareholder which is juristic person incorporated under foreign laws, subject to the following conditions:


- Affidavit or Certificate of Incorporation of such juristic person may be issued by either the government authority of the country in where such juristic person is situated or by an officer of such juristic person, provided that such an Affidavit or Certificate of incorporation must contain the name of the juristic person, the address of the head office of the juristic person, and the name(s) of the person(s) having authority to sign on behalf of the juristic person together with any restrictions or conditions of the power of such person(s); and

- English translation is required to be attached for any original document which is not made in English and such translation must be certified by the authorize.

# Procedures for attending the 2024 Annual General Shareholders' Meeting

# S.D. Avenue hotel, Pinklao Room 3 Floor

Monday April 28, 2025



Stamp duty of Baht 20		Р	roxy Form A.		
Bant 20			Made at		
			Date		
(1) l/w	e			, Nationality	,
				, Tembol/Sub-area	
Amphoe/Area		., Province		, Postal code	;
(2) Be	ing the shareholder of	Intermedical	Care and La	b Hospital Public Com	pany Limited, holding
a total number of	of	share(s), repre	esenting a total r	number of	vote(s) comprising :
		ordinary share(	s), representing		Vote(s);
	k	preferred share(	s), representing		Vote(s);
(3) Hereby appoint either one of the following persons:					
	] (1)			, Age	Years,
Residence No,.	, R	oad	, T	embol/Sub-area	,
Amphoe/Area .	, Pr	ovince	F	Postal code	; or
	(2) Miss Tiwa	aporn Kantas	suwon	Age	55 Years,
Residence No.		Road	Bangwaek	<del>Tembol</del> / Sub-area	Bangwaek,
District/Area	Pasijaroen	Province	Bangkok	Postal code	
	(3) Mr. Waro	kart Tapasa	anant	Age	48 Years,
Residence No.	442	Road	Bangwaek	Tembol/ Sub-area	Bangwaek,
District/Area	Pasijaroen	Province	Bangkok	Postal code	10160

Individually, as my/our proxy to attend and vote at The Annual General Meeting of Shareholders for the Year 2025 On Monday, April 28, 2025 at 9:00 AM. At the S.D. Avenue hotel, Pinklao Room 3 Floor, 94 Borommarat Chachonnani Road, Bang Bamru, Bang Phlat, Bangkok 10700, Thailand. or at any adjournment thereof.

Any action(s) carried out by/decision(s) made by the proxy at the Meeting is/are regarded as carried out by me/us.

Signed ...... Grantor

Signed ..... Proxy

(.....)

<u>Remark</u> A shareholder appointing the proxy must authorize only one proxy to attend and vote at the meeting and shall not allocate the number of shares to several proxies to vote separately

	1	Attachment 10
Stamp duty of Baht 20	Proxy Form B.	
	Made at	
	Date	
(4) 14.	n Niedława Ita	
	ve, Nationality, , Road, Tembol/Sub-area	
	, Province, Postal code	
	ing the shareholder of Intermedical Care and Lab Hospital Public Company	
	of share(s), representing a total number of vot	_
	ordinary share(s), representing	Vote(s);
	preferred share(s), representing	Vote(s);
(3) He	ereby appoint either one of the following persons:	
	(1), Age	Years,
Residence No,.	, Road, Tembol/Sub-area	,
Amphoe/Area	, Province, Postal code	; or
	(2) Miss Tiwaporn Kantasuwon Age	Years,
Residence No.		angwaek,
District/Area	PasijaroenProvince Bangkok Postal code 1016	<u>0;</u> or
	(3) Mr. Warokart Tapasanant Age	Years,
Residence No	442 Road Bangwaek Tembol/ Sub-area E	
	PasijaroenProvince Bangkok Postal code 1016	-
,		
	dually, as my/our proxy to attend and vote at The Annual General Meeting of Sharehol day, April 28, 2025 at 9:00 AM. At the S.D. Avenue hotel, Pinklao Room 3 Floor,	
	Road, Bang Bamru, Bang Phlat, Bangkok 10700, Thailand. or at any adjournment there	
	the said Meeting, I/we wish my/our voting right(s) will be exercised by the proxy as foll	
		204
_	<ul><li>da 1 : To consider and adopt the minutes of the AGM of Shareholders for the Year 20</li><li>(a) I/We grant the proxy the right to consider and vote on my/our behalf in all respects</li></ul>	
	(b) I/We grant the proxy the right to vote in accordance with my/our intention as follow	
	Approve Disapprove Abstain	
Agenc	da 2: To consider and acknowledge the operating results for the 2024 and approve the	e annual financial
	statements ended on December 31, 2024	
	(a) I/We grant the proxy the right to consider and vote on my/our behalf in all respects	
	(b) I/We grant the proxy the right to vote in accordance with my/our intention as follow	s:
	Approve Disapprove Abstain	
Agenc	da 3: To consider and approve no profit allocation and no dividend payment for 2024	l.
	(a) I/We grant the proxy the right to consider and vote on my/our behalf in all respects as	s the proxy deems appropriate.
	(b) I/We grant the proxy the right to vote in accordance with my/our intention as follow	s:
	Approve Disapprove Abstain	

Agenda 4 : To consider and approval of the re-appointment of Directors who retire by rotation and the			
nomination of a new director.			
(a) I/We grant the proxy the right to consider and vote on my/our behalf in all respects as the proxy deems appropriate.			
(b) I/We grant the proxy the right to vote in accordance with my/our intention as follows:			
Election of the directors in whole:			
Approve Disapprove Abstain			
Election of individual directors:			
4.1 Director name <u>Mr. Thanavath</u> Phonvichai			
Approve Disapprove Abstain			
4.2 Director name <u>Mr. Boonyarit</u> Kalayanamit			
Approve Disapprove Abstain			
4.3 Director name Mr. Sukhum Karnchanapimai			
Approve Disapprove Abstain			
Agenda 5 : To consider and approve of the Directors' remuneration for the Year 2025.			
(a) I/We grant the proxy the right to consider and vote on my/our behalf in all respects as the proxy deems appropriate.			
(b) I/We grant the proxy the right to vote in accordance with my/our intention as follows:			
Approve Disapprove Abstain			
Agenda 6 : To consider and approval of the appointment of Auditor and determination of audit fee for the Year 2025.			
(a) I/We grant the proxy the right to consider and vote on my/our behalf in all respects as the proxy deems appropriate.			
(b) I/We grant the proxy the right to vote in accordance with my/our intention as follows:			
Approve Disapprove Abstain			
Agenda 7 : To consideration of other matters (if any)			
(a) I/We grant the proxy the right to consider and vote on my/our behalf in all respects as the proxy deems appropriate.			
(b) I/We grant the proxy the right to vote in accordance with my/our intention as follows:			
Approve Disapprove Abstain			
(5) Victing by the proxy in respect of any agonda that is not in compliance with this Proxy From shall be invalid			

(5) Voting by the proxy in respect of any agenda that is not in compliance with this Proxy From shall be invalid and shall not constitute my/our voting as a shareholder.

(6) If I/we have not expressed my/our intention to vote on any agenda, or if such intention is not clearly expressed, or if the Meeting considers and votes on any matter other than those specified above, including amending or adding any fact, the proxy shall be entitled to consider and vote on my/our behalf in all respects as the proxy deems appropriate.

All acts performed by the Proxy during the course of the Meeting, except for the vote of the Proxy which is not in accordance with this Proxy From, shall bind me/us as if I/We performed such act.

Signed ...... Grantor

Signed ..... Proxy

(.....)

<u>Remark :</u> 1. A shareholder appointing the proxy must authorize only one proxy to attend and vote at the meeting and shall not allocate the number of shareholder to several proxies to vote separately.

- 2. In the agenda of appointment of director, shareholder is able to elect the whole board of directors or only certain directors.
- 3. If any additional item on the agenda is to be considered, the proxy may vote on such item in Supplemental Proxy Form B as attached.

# Regular Continued Proxy (From B.)

Authorization on behalf of the Shareholder of <u>Intermedical Care and Lab Hospital Public Company Limited</u>.

As only one of my / our proxy to attend and vote on my / our behalf of the General Meeting of Shareholders for the year 2025 to be held On Monday, April 28, 2025 at 9:00 AM. At the S.D. Avenue hotel, Pinklao Room 3 Floor, 94 Borommarat Chachonnani Road, Bang Bamru, Bang Phlat, Bangkok 10700, Thailand, or at any adjournment thereof to the date, time and venue

Agenda No	Subject :		
(a) The Proxy is entitled	d to cast the votes on m	y / our behalf at its own direction.	
_		ce with my / our following instruction:	
	Object	Abstain	
Agenda No	Subject :		
(a) The Proxy is entitled	d to cast the votes on m	y / our behalf at its own direction.	
(b) The Proxy must cas	st the votes in accordan	ce with my / our following instruction:	
	Object	Abstain	
		_	
Agenda No	Subject :		
(a) The Proxy is entitled	d to cast the votes on m	y / our behalf at its own direction.	
(b) The Proxy must cas	st the votes in accordan	ce with my / our following instruction:	
	Object	Abstain	
		—	
Agenda No	Subject :		
(a) The Proxy is entitled	d to cast the votes on m	y / our behalf at its own direction.	
(b) The Proxy must cas	t the votes in accordan	ce with my / our following instruction:	
Approve	Object	Abstain	
Agenda No	Subject :		
(a) The Proxy is entitled	d to cast the votes on m	y / our behalf at its own direction.	
		ce with my / our following instruction:	
	Object	Abstain	

Ager	ıda No	. Subject :	
	(a) The Proxy is entitled to	o cast the votes on my / c	our behalf at its own direction.
	(b) The Proxy must cast th	ne votes in accordance v	vith my / our following instruction:
Name	e of Director :		
	Approve	Object	Abstain
Ager	nda No	. Subject :	
	(a) The Proxy is entitled to	o cast the votes on my / c	our behalf at its own direction.
	(b) The Proxy must cast th	ne votes in accordance v	vith my / our following instruction:
	Approve	Object	Abstain
Ager	nda No	. Subject :	
	(a) The Proxy is entitled to	o cast the votes on my / c	our behalf at its own direction.
	(b) The Proxy must cast th	ne votes in accordance v	vith my / our following instruction:
	Approve	Object	Abstain

Stamp duty of	
Baht 20	

# Proxy (Form C)

(For foreign shareholders who have custodian in Thailand only)

	Made at			
_		We Address		
As t	ne custodian	an of being a shareholder of Intermedical (	Care	
and	Lab Hospital	tal Public Company Limited.		
Hold	ling the total a	al amount of shares with the voting rights of	otes	
as fo	ollows:			
Ordi	nary share	shares with the voting rights of	otes	
	(2) Here	erey appoint		
		(1), Age	ears,	
Resi	dence No,	, Tembol/Sub-area	,	
Am	ohoe/Area	, Province, Postal code	; or	
		(2) <u>Miss Tiwaporn Kantasuwon</u> Age	ears,	
Resi	dence No.	442 Road Bangwaek Tembel/ Sub-areaBangwaek	,	
Dist	ict/Area	PasijaroenProvinceBangkokPostal code10160	; or	
		(3) <u>Mr. Warokart Tapasanant</u> Age	ears,	
Resi	dence No	442	,	
Disti	rict/Area	PasijaroenProvince Bangkok Postal code 10160		
	As only	ly one of my / our proxy to attend and vote on my / our behalf of the General Meeting of Shareholder	s for	
the	/ear 2025 to	to be held On Monday, April 28, 2025 at 9:00 AM. At the S.D. Avenue hotel, Pinklao Room 3 F	loor,	
94 E	orommarat C	t Chachonnani Road, Bang Bamru, Bang Phlat, Bangkok 10700, Thailand, or at any adjournment the	ereof	
to th	e date, time a	e and venue.		
	(3) I/We	Ve authorize my / our Proxy to cast the votes according to my / our intentions as follows:		
	Agenda	da 1 : To consider and adopt the minutes of the AGM of Shareholders for the Year 2024		
	(a	(a) I/We grant the proxy the right to consider and vote on my/our behalf in all respects as the proxy de	eems appropriate.	
(b) I/We grant the proxy the right to vote in accordance with my/our intention as follows:				
		Approve Disapprove Abstain		
	Agenda	da 2:To consider and acknowledge the operating results for the 2024 and approve the annual fina	ncial	
		statements ended on December 31, 2024		
	(a	(a) I/We grant the proxy the right to consider and vote on my/our behalf in all respects as the proxy de	eems appropriate.	
	(b) I/We grant the proxy the right to vote in accordance with my/our intention as follows:			
		Approve Disapprove Abstain		

Agenda 3 : To consider and approve no profit allocation and no dividend payment for 2024.				
(a) I/We grant the proxy the right to consider and vote on my/our behalf in all respects as the proxy deems appropriate.				
(b) I/We grant the proxy the right to vote in accordance with my/our intention as follows:				
Approve Disapprove Abstain				
Agenda 4 : To consider and approval of the re-appointment of Directors who retire by rotation and nomination of a new director				
(a) I/We grant the proxy the right to consider and vote on my/our behalf in all respects as the proxy deems appropriate.				
(b) I/We grant the proxy the right to vote in accordance with my/our intention as follows:				
Election of the directors in whole:				
Approve Disapprove Abstain				
Election of individual directors:				
4.1 Director name <u>Mr. Thanavath</u> Phonvichai				
Approve Disapprove Abstain				
4.2 Director name <u>Mr. Boonyarit</u> Kalayanamit				
Approve Disapprove Abstain				
4.3 Director name <u>Mr. Sukhum Karnchanapimai</u>				
Approve Disapprove Abstain				
Agenda 5 : To consider and approve of the Directors' remuneration for the Year 2025.				
(a) I/We grant the proxy the right to consider and vote on my/our behalf in all respects as the proxy				
deems appropriate.				
(b) I/We grant the proxy the right to vote in accordance with my/our intention as follows:				
Approve Disapprove Abstain				
Agenda 6 : To consider and approval of the appointment of Auditor and determination of audit fee for the Year 2025.				
(a) I/We grant the proxy the right to consider and vote on my/our behalf in all respects as the proxy deems appropriate.				
(b) I/We grant the proxy the right to vote in accordance with my/our intention as follows:				
Approve Disapprove Abstain				
Agenda 7 : To consideration of other matters (if any)				
(a) I/We grant the proxy the right to consider and vote on my/our behalf in all respects as the proxy				
deems appropriate.				
(b) I/We grant the proxy the right to vote in accordance with my/our intention as follows:				
Approve Disapprove Abstain				
(5) Vote of the Proxy in any Agenda which is not in accordance with this From of Proxy shall be invalid and				

shall not the vote of the Shareholder.

(6) In case I do not specify the authorization or the authorization is unclear, or if the meeting considers or resolves any matter other than those stated above, or it there is any change or amendment to any fact, the proxy shall be authorized to consider and vote the matter on my / our behalf as the Proxy deems appropriate.

For any act performed by the Proxy at the Meeting, it shall be deemed as such acts had been done by me / us in all respects except for vote of the proxy which is not in accordance with this Proxy From.

Signed ..... Grantor

(.....)

Signed..... Proxy

(.....)

<u>Remarks</u> 1. The Shareholder appointing the Proxy must authorize only one proxy to attend and vote at the meeting and shall not allocate the number of shares to several proxies to vote separately.

- 2. In the agenda relating the election of Directors, it is applicable to elect either nominated directors as a whole or elect each nominated director individually.
- 3. In case there are agenda other than the agenda specified above, the additional statement can be specified by the Shareholder in the Regular Continued Proxy From C. as enclosed.

# Regular Continued proxy (From C.)

Authorization on behalf of the Shareholder of Intermedical Care and Lab Hospital Public Company Limited.

As only one of my / our proxy to attend and vote on my / our behalf of the General Meeting of Shareholders for the year 2025 to be held On Monday, April 28, 2025 at 9:00 AM. At the S.D. Avenue hotel, Pinklao Room 3 Floor, 94 Borommarat Chachonnani Road, Bang Bamru, Bang Phlat, Bangkok 10700, Thailand, or at any adjournment thereof to the date, time and venue

Agenda No	. Subject :	
(a) The Proxy is entitled t	o cast the votes on my /	our behalf at its own direction.
(b) The Proxy must cast t	he votes in accordance	with my / our following instruction:
Approve	Object	Abstain
	Cubicct	
	Subject :	
(a) The Proxy is entitled t	o cast the votes on my /	our behalf at its own direction.
(b) The Proxy must cast t	he votes in accordance	with my / our following instruction:
Approve	Object	Abstain
Agenda No	Subject :	
(a) The Proxy is entitled t	o cast the votes on my /	our behalf at its own direction.
(b) The Proxy must cast t	he votes in accordance	with my / our following instruction:
Approve	Object	Abstain
Agenda No	Subject :	
	-	our behalf at its own direction.
(b) The Proxy must cast t	he votes in accordance	with my / our following instruction:
Approve	Object	Abstain
Agenda No	. Subject :	
(a) The Proxy is entitled t	o cast the votes on my /	our behalf at its own direction.
		with my / our following instruction:
	Object	Abstain

Agenda No Subject :	
(a) The Proxy is entitled to cast the votes on my / our behalf at its own direction.	
(b) The Proxy must cast the votes in accordance with my / our following instruction:	
Name of Director :	
Approve Object Abstair	
Agenda No Subject :	
(a) The Proxy is entitled to cast the votes on my / our behalf at its own direction.	
(b) The Proxy must cast the votes in accordance with my / our following instruction:	
Approve Object Abstair	
Agenda No Subject :	
(a) The Proxy is entitled to cast the votes on my / our behalf at its own direction.	
(b) The Proxy must cast the votes in accordance with my / our following instruction:	
Approve Object Abstair	

# Map of the Meeting Venue

S.D. Avenue hotel, Pinklao Room 3 Floor, 94 Borommarat Chachonnani Road, Bang Bamru, Bang Phlat, Bangkok 10700, Thailand

